Replication of Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes (TRITON-TIMI 38 Trial)

January 13, 2020

1. RCT Details

This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases.

1.1 Title

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes (TRITON–TIMI 38 trial)

1.2 Intended aim(s)

To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months.

1.3 Primary endpoint for replication and RCT finding

The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding.

1.4 Required power for primary endpoint and noninferiority margin (if applicable)

We calculated that a total of 875 primary end points would be required for the study to have a 90% power to detect a 20% reduction in the relative risk of the primary end point among patients with unstable angina or non–ST-elevation myocardial infarction receiving prasugrel, as compared with clopidogrel.

1.5 Primary trial estimate targeted for replication

HR = 0.81 (95% CI 0.73–0.90) comparing prasugrel to clopidogrel (Wiviott et al., 2007)

2. Person responsible for implementation of replication in Aetion

Ajinkya Pawar, Ph.D. implemented the study design in the Aetion Evidence Platform. S/he is not responsible for the validity of the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform.

3. Data Source(s)

United/Optum, MarketScan

4. Study Design Diagram

The study design diagram visualizes key aspects of the longitudinal study design for expedited review.


Design Diagram – TRITON-TIMI 38 TRIAL REPLICATION
Percutaneous Coronary Intervention (PCI) hospitalization
Enrollment assessment window Days [-180, PCI]
INCL: Unstable angina, NSTEMI, or [STEMI or Acute MI] Days [-28, PCI]
Cohort Entry Date (Day 0) [Dispensation of Prasugrel] OR Comparator (i.e. Clopidogrel)] Days [PCI discharge, 14]
Washout Window (No Prasugrel or Comparator use) Days [-180, -1]
EXCL: Hemorrhagic stroke Days [-All available data, PCI]
EXCL:, Intracranial neoplasm, AV malformation, or Cerebral aneurysm Days [-180, PCI]
EXCL: Ischemic stroke Days [-90, PCI]
EXCL: Ventricular arrhythmias, Heart failure or oxygen use, Active internal bleeding + Bleeding diathesis Days [-180, 0]
Additional enrollment assessment window Days [PCI discharge, 14]
INCL: Age >18 years Days [at PCI hospitalization]
EXCL: Cardiogenic shock Days [during PCI hospitalization]
EXCL: Thrombocytopenia or Anemia Days [during PCI hospitalization]
EXCL: Clopidogrel, Prasugrel, or Ticlopidine use Days [-5, -1]
EXCL: [>150 days supply out of 180 for NSAIDs or Celecoxib], CCI ≥ 10, known severe hepatic dysfunction, or [Schizophrenia, Psychosis, Delirium, Dementia, Drug abuse or dependence, or Alcohol abuse or dependence] Days [-180, 0]
Covariate Assessment Window Days [-180, 0]
PRIMARY OUTCOME(S): 3P-MACE (MI/Stroke/CV Death)
Follow Up Window Days [1, censor[a]]
Day 0
Time
[a] Censoring criteria
Occurrence of outcome
Disenrollment
Specific date reached
Death
Nursing home admission
End of index exposure
Start of additional exposure
Switching between study drugs
Initiation of ticagrelor

5. Cohort Identification

5.1 Cohort Summary

This study will involve a new user, parallel group, cohort study design comparing prasugrel 90mg to clopidogrel 75mg. The patients will be required to have continuous enrollment during the baseline period of 180 days before initiation of prasugrel 90mg or a comparator drug (cohort entry date). Follow-up for the outcome (3P-MACE), begins the day after drug initiation.

5.2 Important steps for cohort formation

New users (defined as no use in 180 days prior to index date) of an exposure and a comparator drug will be identified.

5.2.1 Eligible cohort entry dates

Market availability of prasugrel in the U.S. started on 2009-07-10.

- For Marketscan: 2009-07-10 to 2017-12-31 (end of data availability).
- For Optum: 2009-07-10 to 2019-03-31 (end of data availability).

5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date

Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided in **Appendix A** and are summarized in the flowcharts below.

5.3 Flowchart of the study cohort assembly

	Optum		**MarketScan**	
	Less Excluded Patients	**Remaining Patients**	**Less Excluded Patients**	**Remaining Patients**
All patients		75,524,500		191,990,035
Patients meeting the cohort entry criteria of moderate to high risk Acute Coronary Syndrome undergoing PCI procedure	-75219388	305,112	-191556394	433,641
Patients with sufficient enrollment period in the claims database	-41910	263,202	-120017	313,624
Patients with moderate to high risk Acute Coronary Syndrome	-144114	119,088	-165792	147,832
Patients initiating clopidogrel 75mg or prasugrel 10mg within 14 days of discharge of PCI hospitalization	-56497	62,591	-54511	93,321

Patients without history of hemorrhagic stroke	-349	62,242	-392	92,929
Patients without intracranial neoplasm, AV malformation, or aneurysm	-186	62,056	-202	92,727
Patients without ischemic stroke occurring 90 days prior to PCI hospitalization	-163	61,893	-255	92,472
Patients with sufficient claims enrollment after PCI hospital discharge	-483	61,410	-1191	91,281
Parent: Final cohort		61,410		91,281
Did not meet cohort entry criteria	-80	61,330	0	91,281
Excluded due to insufficient enrollment	0	61,330	0	91,281
Patients with no prior use of clopidogrel	-3135	58,195	-3653	87,628
Patients with no prior use of prasugrel	-535	57,660	-958	86,670
Patients without qualification in >1 exposure category	-18	57,642	-20	86,650
Patients age 18 years or older	-2	57,640	0	86,650
Patients without cardiogenic shock during PCI hospitalization	-1811	55,829	-2457	84,193
Patients without refractory ventricular arrhythmias	-5341	50,488	-7235	76,958
Patients without New York Heart Association Class IV congestive heart failure	-416	50,072	-265	76,693
Patients without active internal bleeding or history of bleeding diathesis	-3974	46,098	-3739	72,954
Patients without thrombocytopenia (platelet count of less than 100,000/mm3)	0	46,098	0	72,954
Patients without anemia (hemoglobin <10 g/Dl)	-886	45,212	-2039	70,915
Patients without a claim for thienopyridine 5 days or less before PCI hospitalization	-1	45,211	-1	70,914
Patients without daily treatments with NSAIDs or COX-2 inhibitors	-394	44,817	-654	70,260
Patients without concomitant medical illness that is potentially associated with reduced survival	-687	44,130	-235	70,025
Patients without severe hepatic dysfunction	-1755	42,375	-2041	67,984
Patients without issues on poor treatment compliance including alcoholism, mental illness, or drug dependence	-2927	39,448	-1981	66,003
Final cohort		**39,448**		**66,003**

6. Variables

6.1 Exposure-related variables:

Study drug:

The study exposure of interest is initiation of Prasugrel. Initiation will be defined by no use of Prasugrel or a comparator in the prior 6 months before treatment initiation (washout period).

Comparator agents:

- Initiators of prasugrel 10mg will be compared to initiators of-
    - Clopidogrel 75mg

6.2 Preliminary covariates:

- Age
- Sex
- Combined Comorbidity Index (CCI), measured over the default baseline covariate assessment period, defined as 180 days prior to and including index date

Covariates listed above represent only a small subset of covariates that will ultimately be controlled for in the design and analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility analysis and the initial power assessment and are listed in Table 1 (**Appendix B**).

6.3 Outcome variables and study follow-up:

6.3.1 Outcome variables

Effectiveness outcomes of interest (definitions provided in **Appendix A**):

- **Primary outcome**: 3-point major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, or CV mortality
- Secondary outcomes: Individual components:
    - Hospital admission for MI (for purposes of this individual component, fatal MI is included)
    - Hospital admission for stroke (for purposes of this individual component, fatal stroke is included)
    - All-cause mortality/CV mortality:
        - All-cause inpatient mortality identified using discharge status codes will be used as a proxy for "CV mortality" in Marketscan
        - In Optum, all-cause inpatient mortality + all-cause mortality for Medicare Advantage patients is used

Control outcome of interest (control outcome only serve to assess aspects of study validity but are not further interpreted):

1. Major bleeding (we expect to see increased risk with prasugrel; Wiviott, 2007)
2. Pneumonia (we expect to see a null association)

Control outcome definition

Outcome	Definition	Comments
Control Outcomes		
Major bleeding	Any inpatient diagnosis of major bleeding -- code list provided in **Appendix A**	Same code list used for both outcome and major bleed exclusion criteria
Pneumonia	Any inpatient diagnosis of pneumonia: * 481 - PNEUMOCOCCAL PNEUMONIA [STREPTOCOCCUS PNEUMONIAE PNEUMONIA] * 482 - OTHER BACTERIAL PNEUMONIA * 483 - PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM * 485 - BRONCHOPNEUMONIA ORGANISM UNSPECIFIED * 486 - PNEUMONIA ORGANISM UNSPECIFIED * 487.0 - INFLUENZA WITH PNEUMONIA * 507 - PNEUMONITIS DUE TO SOLIDS AND LIQUIDS * 482.0 - PNEUMONIA DUE TO KLEBSIELLA PNEUMONIAE * 482.1 - PNEUMONIA DUE TO PSEUDOMONAS * 482.2 - PNEUMONIA DUE TO HEMOPHILUS INFLUENZAE * 482.3 - PNEUMONIA DUE TO STREPTOCOCCUS * 482.30 - PNEUMONIA DUE TO STREPTOCOCCUS UNSPECIFIED * 482.31 - PNEUMONIA DUE TO STREPTOCOCCUS GROUP A * 482.32 - PNEUMONIA DUE TO STREPTOCOCCUS GROUP B * 482.39 - PNEUMONIA DUE TO OTHER STREPTOCOCCUS * 482.4 - PNEUMONIA DUE TO STAPHYLOCOCCUS * 482.40 - PNEUMONIA DUE TO STAPHYLOCOCCUS UNSPECIFIED * 482.41 - METHICILLIN SUSCEPTIBLE PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS * 482.42 - METHICILLIN RESISTANT PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS * 482.49 - OTHER STAPHYLOCOCCUS PNEUMONIA * 482.8 - PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA * 482.81 - PNEUMONIA DUE TO ANAEROBES * 482.82 - PNEUMONIA DUE TO ESCHERICHIA COLI [E.COLI] * 482.83 - PNEUMONIA DUE TO OTHER GRAM-NEGATIVE BACTERIA * 482.84 - PNEUMONIA DUE TO LEGIONNAIRES' DISEASE * 482.89 - PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA * 482.9 - BACTERIAL PNEUMONIA UNSPECIFIED * 483.0 - PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE * 483.1 - PNEUMONIA DUE TO CHLAMYDIA * 483.8 - PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM	PPV = 85% (Aronsky, et al.; 2005); Note- The corresponding ICD-10 codes will also be used

	* 507.0 - PNEUMONITIS DUE TO INHALATION OF FOOD OR VOMITUS * 507.1 - PNEUMONITIS DUE TO INHALATION OF OILS AND ESSENCES * 507.8 - PNEUMONITIS DUE TO OTHER SOLIDS AND LIQUIDS	

6.3.2 Study follow-up

Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on the day of cohort entry. Because adherence in the real-world databases is expected to be much worse than in the trial, the AT analysis is the **primary** analysis, as it targets the relative hazard of outcomes on treatment.

For the AT analyses, the follow-up will start the day after initiation of prasugrel and comparator and will continue until the earliest date of the following events:

- The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,
- The date of end of continuous registration in the database,
- End of the study period,
- Measured death event occurs,
- Nursing home admission
    - Nursing home admissions are considered a censoring event because the data sources utilized typically provide little to no data on a patient, particularly on drug utilization, after admission. We will utilize this as an exclusion reason for cohorts for the same reason.
- The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug (prasugrel and comparator) plus a defined grace period (i.e., 30 days after the end of the last prescription's days' supply in main analyses).
- The date of augmentation or switching from an exposure to a comparator
- Initiation of ticagrelor

For the ITT analyses, the censoring based on the augmentation/switching and treatment discontinuation will be replaced with a maximum allowed follow-up time of 365 days.

7. Initial Feasibility Analysis

Aetion report links:
Optum: https://bwh-dope.aetion.com/projects/details/989/results/46156/result/0
Marketscan: https://bwh-dope.aetion.com/projects/details/990/results/46157/result/0

Date conducted: December 15, 2019

Complete Aetion feasibility analysis using age, sex, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the outcome. No measures of association will be computed nor will incidence rates stratified by treatment group.

- Report patient characteristics by treatment group
- Report summary parameters of the overall study population
- Report median follow-up time by treatment group
- Report reasons for censoring in the overall study population

8. Initial Power Assessment

Aetion report links:
Optum: https://bwh-dope.aetion.com/projects/details/989/results/46159/result/0
Marketscan: https://bwh-dope.aetion.com/projects/details/990/results/46158/result/0

Date conducted: December 15, 2019

In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined comorbidity index. Power calculations are based on the formulas from Chow et al. (2008).

In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage.

Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined comorbidity index. Power calculations are based on the formulas from Chow et al. (2008).

Reviewed by PI:	Jessica Franklin	Date reviewed:	12/16/19
Reviewed by FDA:	David Martin	Date reviewed:	1/2/20
Reasons for stopping analysis (if required):			

9. Balance Assessment after PS matching

Aetion report links (Prasugrel vs. clopidogrel):
Optum: https://bwh-dope.aetion.com/projects/details/989/results/46940/result/0
Marketscan: https://bwh-dope.aetion.com/projects/details/990/results/46941/result/0

Date conducted: 01/05/2020

After review of initial feasibility and power analyses, complete creation of the remaining covariates (see Table 1 below for list of covariates). Again, using the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete list of covariates (excluding laboratory values, which are missing in some patients).

- Provide plot of PS distributions stratified by treatment group.

  Note- Please refer to **Appendix B**.

- Report covariate balance after matching.

  Note- For Table 1, please refer to **Appendix B**.

- Report reasons for censoring by treatment group.

	Overall	**Referent**	**Exposure**

Dummy Outcome	0 (0.00%)	0 (0.00%)	0 (0.00%)
Death	123 (0.28%)	70 (0.32%)	53 (0.24%)
Start of an additional exposure	3,840 (8.75%)	580 (2.64%)	3,260 (14.86%)
End of index exposure	22,870 (52.14%)	11,391 (51.94%)	11,479 (52.34%)
Specified date reached	3,735 (8.51%)	2,262 (10.31%)	1,473 (6.72%)
End of patient enrollment	12,361 (28.18%)	7,033 (32.07%)	5,328 (24.29%)
Switch to ticagrelor (for censoring) + nursing home admission	935 (2.13%)	596 (2.72%)	339 (1.55%)

- Report follow-up time by treatment group.

Median Follow-Up Time (Days) [IQR]		
Patient Group	**Optum**	**Marketscan**
Overall Patient Population	276 [98-453]	312 [122-481]
Referent	332 [124-532]	344 [144-530]
Exposure	222 [82-405]	281 [111-443]

- Report overall risk of the primary outcome.

	Optum	**Marketscan**
Risk per 1,000 patients (MACE)	58.63	45.09

10. Final Power Assessment

Date conducted:

- Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. All other parameters in the table should be the same as in Section 8. If the study is to be implemented in more than one database, copy and paste excel sheet to report power for each database separately and for the pooled analysis that uses data from all databases together. Power calculations are based on the formulas from Chow et al. (2008).
    - Pooled
        - **For prasugrel 10mg vs. clopidogrel 75mg (Primary outcome- MACE)**

Superiority Analysis		**Non-inferiority Analysis**	
Number of patients matched		Number of patients matched	
Reference	21,932	Reference	21,932
Exposed	21,932	Exposed	21,932
Risk per 1,000 patients	51.86	Risk per 1,000 patients	51.86
Desired HR from RCT	0.8	Assumed HR from RCT	1
Alpha (2-sided)	0.05	Alpha (2-sided)	0.05
		Non-inferiority margin	1.3
Number of events expected	2274.78704	Number of events expected	2274.78704
Power	0.999612288	Power	0.999991333

- Optum
  - **For prasugrel 10mg vs. clopidogrel 75mg (Primary outcome- MACE)**

Superiority Analysis		**Non-inferiority Analysis**	
Number of patients matched		Number of patients matched	
Reference	6,835	Reference	6,835
Exposed	6,835	Exposed	6,835
Risk per 1,000 patients	58.63	Risk per 1,000 patients	58.63
Desired HR from RCT	0.8	Assumed HR from RCT	1
Alpha (2-sided)	0.05	Alpha (2-sided)	0.05
		Non-inferiority margin	1.3
Number of events expected	801.4721	Number of events expected	801.4721
Power	0.884670943	Power	0.960270972

- MarketScan
  - **For prasugrel 10mg vs. clopidogrel 75mg (Primary outcome- MACE)**

Superiority Analysis		**Non-inferiority Analysis**	
Number of patients matched		Number of patients matched	
Reference	15,097	Reference	15,097
Exposed	15,097	Exposed	15,097
Risk per 1,000 patients	45.09	Risk per 1,000 patients	45.09
Desired HR from RCT	0.8	Assumed HR from RCT	1
Alpha (2-sided)	0.05	Alpha (2-sided)	0.05
		Non-inferiority margin	1.3
Number of events expected	1361.44746	Number of events expected	1361.44746
Power	0.984488939	Power	0.998013942

- Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of advisory board. Reviewers evaluate the results of the analyses described above in Sections 9 and 10, including numbers of patients, balance in patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates of outcomes and study power.

Reviewed by PI:	Jessica Franklin	Date reviewed:	12/16/19
Reviewed by FDA:	David Martin	Date reviewed:	01/02/2020
Reasons for stopping analysis (if required):			

11. Study Confidence and Concerns

Deadline for voting on study confidence and listing concerns: 1/10/20

- If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps.
- All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the individual respondent.

12. Register study protocol on clinicalTrials.gov

Date conducted:

- Register the study on clinicalTrials.gov and upload this document.

13. Comparative Analyses

Aetion report name:
Date conducted:

13.1 For **primary analysis**:

- In the PS-matched cohort from Section 9, calculate the HR for each outcome for prasugrel versus clopidogrel patients using a Cox proportional hazards model.

13.2 For secondary analyses:

- In both pre-matched cohorts, perform asymmetrical trimming to remove patients with PS values below the 2.5th percentile of treated patients and above the 97.5th percentile of untreated patients. In the trimmed cohort, calculate the HR for prasugrel versus referent patients using a Cox proportional hazards model, adjusting for deciles of the PS.

14. Requested Results

14.1 Results from primary and secondary analyses;

Analysis	No. exposed events	No. referent events	Exposed rate	Referent rate	HR (95% CI)
Crude					
Primary analysis					
Analysis 2					
...					

HR, Hazard Ratio; CI, Confidence Interval.

15. References

Aronsky, Dominik, et al. Accuracy of Administrative Data for Identifying Patients with Pneumonia. American Journal of Medical Quality. 2005: 20(6);319–28. doi:10.1177/1062860605280358.

Chow S, Shao J, Wang H. 2008. *Sample Size Calculations in Clinical Research*. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. **page 177**

Wiviott et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357:2001-15.

Appendix A

#	TRITON-TIMI trial definitions	Implementation in routine care	References	Color coding
	Trial details- HR = 0.81 (95% CI 0.73–0.90)		Please see the following Google Drive for further details or any missing information: https://drive.google.com/open?id=1WD618wrywYjEaXzfLTcuK-VCcnb6h-gV	Adequate mapping in claims
	EXPOSURE vs. COMPARISON		Not all ICD-10 codes are not listed in this document because of excel cell size limitations and excessive number of ICD-10 codes. Full ICD-10 code lists will be available in the above Google Drive Folder (link above). ICD-9 to ICD-10 code conversions were completed using a SAS macro that implements forward/backward mapping based on the CMS ICD-9 to ICD-10 mapping: https://www.nber.org/data/icd9-icd-10-cm-and-pcs-crosswalk-general-equivalence-mapping.html	Intermediate mapping in claims
	Prasugrel (10mg daily) vs clopidogrel (75mg daily)	Exposure: Prasugrel 10mg Clopidogrel 75mg	**KEY TIME POINTS:** **Index event :** Onset of Acute coronary syndrome (ACS) which becomes the indication for study drug (prasugrel or clopidogrel) initiation **Index hospitalization:** Hospitalization for the treatment (PCI) of index event **Drug initiation date:** New prescription claim for the study drug in patients with a record of index hospitalization in the previous 2 weeks. * We assume that the patient first initates study drug in hospital and continues to be part of the initiator group as long as a prescription is filled within 2 weeks of discharge of ACS event.	Poor mapping or cannot be measured in claims
	PRIMARY OUTCOME			Can't be measured in claims but not important for the analysis
	Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke	**Measured 1 day after drug initiation in diagnosis position specified below and inpatient care setting:** **Inpatient mortality/MI/Stroke –** **For MI** Any diagnosis position in inpatient care setting ICD-9 Dx 410.X (acute myocardial infarction) excluding 410.x2 (subsequent episode of care) **For stroke** Primary diagnosis position in inpatient care setting ICD-9 discharge diagnosis: 430.xx Subarachnoid hemorrhage (SAH) 431.xx Intracerebral hemorrhage (ICH) 433.x1 Occlusion and stenosis of precerebral arteries with cerebral infarction 434.xx (excluding 434.x0) Occlusion and stenosis of cerebral arteries with cerebral infarction 436.x Acute, but ill-defined cerebrovascular events **Mortality- See Mortality Sheet.**	For MI: ➔PPV 94% in Medicare claims data [Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. American heart journal 2004;148:99-104.] ➔PPV 88.4% in commercially-insured population [Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiology and Drug Safety 2010;19:596-603.] For stroke: PPV of 85% or higher for ischemic stroke PPV ranging from 80% to 98% for hemorrhagic stroke ➔[Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiology and Drug Safety 2012;21 Suppl 1:100-28.] ➔[Tirschwell DL, Longstreth WT, Jr. Validating administrative data in stroke research. Stroke; a journal of cerebral circulation 2002;33:2465-70.] ➔[Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiology and drug safety 2008;17:20-6.]	
	INCLUSION CRITERIA			
1	Acute coronary syndrome based on the disease diagnostic criteria with planned PCI (ACS definition; one of the following):	**The hospitalization with inpatient CPT/ICD-9 procedure code for PCI becomes the anchoring event for measuring 1a, 1b, 1c below. (Anchoring event = Index hospitalization)** **PCI:** CPT code: 92920, 92921, 92924, 92925, 92928, 92929, 92933, 92934 ICD-9 procedure codes: 00.66, 36.00, 36.06, 36.07, 36.09	Blumenthal DM, Valsdottir LR, Zhao Y, et al. A Survey of Interventional Cardiologists' Attitudes and Beliefs About Public Reporting of Percutaneous Coronary Intervention. JAMA Cardiol. 2018;3(7):629–634. doi:10.1001/jamacardio.2018.1095	
1a.	**Moderate to high risk Unstable angina:** A history of chest discomfort or ischemic symptoms of 10 min or longer at rest, 72 h or less before randomization, with persistent or transient ST-segment deviation 1 mm or higher in one or more electrocardiogram (ECG) leads without elevation of creatine kinase–MB (CK-MB) or troponin T or I but with a TIMI risk score 321 or greater	**Measured 4 weeks prior to index hospitalization in inpatient, primary position** **Unstable angina:** ICD-9 : 411.xx ICD-10: I24.1x, I20.0x, I25.1x, I25.7x, I24.0x, I24.8x, I24.9x	Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 http://dx.doi.org/10.1136/bmj.k119 Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177	
1b.	**ii. Moderate to high-risk NSTEMI:** A history of chest discomfort or ischemic symptoms of 10 min or longer at rest, 72 h or less before randomization with no evidence of persistent ST-segment elevation. Subjects must also have CK-MB or troponin T or I greater than the upper limit of normal (ULN) and a TIMI risk score 3 or greater. If CK-MB or troponin is not available, total CK 2 times or greater ULN is acceptable	**Measured 4 weeks prior to index hospitalization in inpatient, primary position** **NSTEMI:** ICD-9: 410.7x , 410.8x, 410.9x but exclude 410.x2 (subsequent episode of care descriptions) **NSTEMI:** ICD-10 **:**I21.4x, I21.9x, I21.Ax, I22.2x	Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 http://dx.doi.org/10.1136/bmj.k119 Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177 Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol. 2014;24(6):500–507. doi:10.2188/jea.je20140076	
1c.	**iii. STEMI:** A history of chest discomfort or ischemic symptoms of greater than 20 minutes duration at rest, within 14 days or less randomization with one of the following ECG features: (a) ST-segment elevation 1 mm or higher in 2 or more contiguous ECG leads (b) New or presumably new left bundle branch block (c) ST-segment depression 1 mm or greater in 2 anterior precordial leads (V1 through V4) with clinical history and evidence suggestive of true posterior infarction	**Measured 4 weeks prior to index hospitalization in inpatient, primary position** **STEMI:** **ICD-10** I21.0x, I21.1x, I21.2x, I22.0x, I22.1x, I22.8x, I22.9x, I23.3x, I22.0x, I22.1x, I22.8, I22.9 **Acute MI:** ICD-9 410.0x–410.6x , but exclude 410.x2 (subsequent episode of care descriptions)	Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 http://dx.doi.org/10.1136/bmj.k119 Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177 Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol. 2014;24(6):500–507. doi:10.2188/jea.je20140076	
2	Legal age (and >18 y) and competent mental condition to provide written informed consent	**Measured at index hospitalization** Age >18		

Appendix A

3	For women of childbearing potential only, test negative for pregnancy between ACS presentation and enrollment (based on a urine or serum pregnancy test) and agree to use a reliable method of birth control during the study	N/A (We account for this criteria as an exclusion criteria)	
	EXCLUSION CRITERIA		
	Cardiovascular exclusion criteria		
1	Cardiogenic shock at the time of randomization	**Measured during index hospitalization in inpatient setting, any position** **Cardiogenic shock:** ICD-9 : 785.51 ICD-10: R57.0	
2	Refractory ventricular arrhythmias	**Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient setting** **Ventricular tachycardia** ICD-9: 427.1 ICD-10: I47.2 **Ventricular fibrillation** ICD-9: 427.4x ICD-10: I49.0x	
3	New York Heart Association class IV congestive heart failure	**Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient setting.** **Heart failure diagnosis:** Any of ICD-9 codes : 428.x, 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 404.93 AND **Oxygen use:** E0424 E0425 E0430 E0431 E0433 E0434 E0435 E0439 E0440 E0441 E0442 E0443 E0444 E0447 E1390 E1391 E1392 E1405 E1406 K0738 S8120 S8121 ICD-9 V46.2 (Other dependence on machines, supplemental oxygen), ICD-10 Z99.81 (Dependence on Supplemental oxygen)	
	Bleeding risk exclusion criteria		
4	Fibrin-specific fibrinolytic therapy less than 24 h before randomization	N/A	
5	Non–fibrin-specific fibrinolytic therapy less than 48 h before randomization	N/A	
6	Active internal bleeding or history of bleeding diathesis	**Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient setting** For **active internal bleeding**, refer to the sheet "Bleeding" or **Bleeding diathesis:** ICD-9: 286.x Coagulation defects 287.x Purpura and other hemorrhagic conditions	Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560–566. doi:10.1002/pds.2109 Huybrechts KF, Gopalakrishnan C, Bartels DB, Zint K, Gurusamy VK, Landon J, et al. Safety and effectiveness of dabigatran and other direct oral anticoagulants compared to warfarin in patients with atrial fibrillation. Clin Pharmacol Ther. 2019 Dec 23.
7	Clinical findings, in the judgment of the investigator, associated with an increased risk of bleeding		
8	Any of the following:		
	a) History of hemorrhagic stroke	**Measured any time prior to index hospitalization in any diagnosis position, inpatient or outpatient setting** Hemorrhagic stroke: ICD-9: 430.xx, 431.xx ICD-10: I60.xx, I61.xx,	Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 http://dx.doi.org/10.1136/bmj.k119 Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177
	b) Intracranial neoplasm, arteriovenous malformation, or aneurysm	**Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient setting** **Intracranial neoplasm** ICD-9: 191.x, 225.0, 225.2, 225.4 ICD-10: C71.x, D32.x, D33.x, **AV malformation (of brain)** ICD-9: 747.81 ICD-10: Q28.2x **Cerebral Aneurysm** ICD-9: 437.3 ICD-10: I67.1	
	c) Ischemic stroke within 3 months prior to screening	**Measured 90 days prior to index hospitalization in any position, inpatient setting.** **Ischemic stroke:** ICD-9: 433.xx, 434.xx, 436.xx ICD-10: I63.xx I65.xx I66.xx	Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 http://dx.doi.org/10.1136/bmj.k119 Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177
9	International normalized ratio known to be greater than 1.5 at the time of screening	N/A	
10	Platelet count of less than 100000/mm3 at the time of screening	**Measured during index hospitalization in inpatient setting, any position** Thrombocytopenia: ICD-10: D69.6, D69.4x, D69.5x, D69.2x, D69.3x ICD-9: 287.3x, 287.4x	
11	Anemia (hemoglobin b10 g/dL) at the time of screening	**Measured during index hospitalization in inpatient setting, any position** ICD-9: 280.0 Iron deficiency anemia secondary to blood loss (chronic) 285.1 (Acute posthemorrhagic anemia), 285.9 (Anemia unspecified)	

Appendix A

	Prior/concomitant therapy exclusion criteria		
12	One or more doses of a thienopyridine 5 d or less before PCI	**Prescription for following drugs 5 days prior to index hospitalization** Clopidogrel, prasugrel, or ticlopidine	
13	Oral anticoagulation or other antiplatelet therapy that cannot be safely discontinued for the duration of the study	N/A	
14	Daily treatment with nonsteroidal antiinflammatory drugs (NSAIDs) or cyclooxygenase-2 inhibitors (COX-2 inhibitors)	**More than 150 days of supply out of 180 days prior to drug initiation** NSAID: aspirin, ibuprofen, naproxen >> OTC cannot be captured COX-2 inhibitors: celecoxib	
	General exclusion criteria		
15	Investigative site personnel directly affiliated with the study or immediate family	N/A	
16	Employed by Eli Lilly and Company; Ube Industries Limited, Daiichi Sankyo Co.; The TIMI Study Group; Quintiles	N/A	
17	Treatment within the last 30 d with an investigational drug or are presently enrolled in another drug or device study	N/A	
18	Previously completed or withdrawn from this study or any other study investigating prasugrel	N/A	
19	Women who are known to be pregnant, have given birth within the past 90 d, or are breast-feeding	N/A	
20	Concomitant medical illness that in the opinion of the investigator is associated with reduced survival	**Following index score measured 180 days prior to drug initiation** Combined comorbidity index CCI >=10	Gagne, Josh J et. al. ""A combined comorbidity score predicted mortality in elderly patients better than existing scores."" J Clin Epidemiol. 2011 Jul;64(7):749-59. doi: 10.1016/j.jclinepi.2010.10.004. Sun, Jenny W et. al. ""Validation of the Combined Comorbidity Index of Charlson and Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10."" Med Care. 2018 Sep;56(9):812. doi: 10.1097/MLR.0000000000000954.
21	Known severe hepatic dysfunction	**Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient setting** **Liver disease** ICD-9 diagnosis: 070.xx, 570.xx- 573.xx, 456.0x-456.2x, 576.8x, 782.4x, 789.5x ICD-9 procedure codes: 39.1x, 42.91	Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 http;//dx.doi.org/10.1136/bmj.k119 Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177
22	Any condition associated with poor treatment compliance including alcoholism, mental illness, or drug dependence	**Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient setting** **Schizophrenia**: ICD-9-CM codes: 295.xx; ICD-10-CM codes: F20.xx **Psychosis:** ICD-9-CM codes: 290.8x, 290.9x, 297.xx, 298.xx, 780.1x; ICD-10-CM codes: F22, F23, F24, F23.3, F23.3, F28, F29, R44.0, R44.2, R44.3 **Delirium:** ICD-9-CM codes: 290.11, 290.3x, 290.41, 291.0x, 292.81, 293.xx; ICD-10-CM codes: F05, F01.51, F03.90, F10.231, F06.2, F06.0 **Dementia:** ICD-9-CM codes: 290.xx, 294.1x, 294.8x, 311.19, 331.82; ICD-10-CM codes: F03.xx, F02.80, F02.81, G31.83, **Drug abuse or dependence:** ICD-9-CM codes: 292.xx, 304.xx, 305.2x-305.9x, 648.3x, 760.72, 760.73, 760.75, 965.0x, 967.xx, 969.4x-969.6x, 969.72-969.79, 970.1, 970.81 ; ICD-10-CM codes: **Alcohol abuse or dependence:** ICD-9-CM codes: 291.xx, 303.xx, 305.0x, 357.5x, 425.5x, 571.0x – 571.3x, E860.0, V11.3; ICD-10-CM codes:	Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 http;//dx.doi.org/10.1136/bmj.k119 Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177
23	Intolerance of or allergy to aspirin, tilopidine, or clopidogrel	N/A	
24	May be unable to cooperate with protocol requirements and follow-up procedures	N/A	

Appendix A

Trial ID	pNDA14
Trial Name (with web links)	TRITON-TIMI 38
Trial Name (with pdf links)	TRITON-TIMI 38
NCT	NCT00097591
Trial category	Primary indication
Run-in period Description	
Run-in period?	?
Therapeutic Area	Cardiology/Vascular Diseases
Study batch	Antiplatelets
RCT Category	1a- Intended S with label change
Brand Name	Efient
Generic Name	prasugrel
Sponsor	Eli Lilly
Year	2009
Measurable endpoint	Primary composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding.
Exposure	Prasugrel
Comparator	Clopidogrel
Population	patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention
Trial finding	HR = 0.81 (95% CI 0.73–0.90)
Notes	
No. of Patients	13,608
Non-inferiority margin	-
Assay Sens. Outcome	
Assay Sens. Endpoint (from trial)	
Finding for potential Assay Sens. Outcome from trial-	
Power	0.90 to detect 20% reduction in the relative risk
Blinding	Double-blinded

Appendix A

Statistical Method	
Approval indication	for the prevention of thrombotic cardiovascular complications in acute coronary syndromes

Appendix A

Mortality- Dependent on data source.

1. All-cause mortality / inpatient mortality
Identified using the vital status file-

Medicare
Identified using the discharge status codes-

Optum-
- 20 = EXPIRED
- 21 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 22 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 23 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 24 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 25 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 26 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 27 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 28 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 29 = EXPIRED TO BE DEFINED AT STATE LEVEL
- 40 = EXPIRED AT HOME (HOSPICE)
- 41 = EXPIRED IN A MEDICAL FACILITY (HOSPICE)
- 42 = EXPIRED - PLACE UNKNOWN (HOSPICE)

Truven-
- 20 - Died
- 22 - Died
- 23 - Died
- 24 - Died
- 25 - Died
- 26 - Died
- 27 - Died
- 28 - Died
- 29 - Died
- 40 - Other died status or Expired at home (Hospice claims only) (depends on year)
- 41 - Other died status or Expired in medical facility (Hospice claims only) (depends on year)

- 42 - Other died status or Expired - place unknown (Hospice claims only) (depends on year)
- 21 - Died or Disch./Transf. to court/law enforcement (depends on year)

2. CV mortality

Information on CV mortality through data linkage with the National Death Index (NDI) will be available for Medicare at a later date. We will conduct secondary analyses using CV mortality at that time.

Appendix A

Major bleeding control outcome: 1 inpatient (any position) Major bleeding exclusion criteria: 1 inpatient (any position) or 2 outpatient diagnosis (separated by 7-365 days)	
562.02	(ICD9) DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.03	(ICD9) DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.12	(ICD9) DIVERTICULOSIS OF COLON WITH HEMORRHAGE
562.13	(ICD9) DIVERTICULITIS OF COLON WITH HEMORRHAGE
568.81	(ICD9) HEMOPERITONEUM (NONTRAUMATIC)
569.3	(ICD9) HEMORRHAGE OF RECTUM AND ANUS
569.83	(ICD9) PERFORATION OF INTESTINE
569.85	(ICD9) ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
569.86	(ICD9) DIEULAFOY LESION (HEMORRHAGIC) OF INTESTINE
578	(ICD9) HEMATEMESIS
578.9	(ICD9) HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
423	(ICD9) HEMOPERICARDIUM
432	(ICD9) NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1	(ICD9) SUBDURAL HEMORRHAGE
432.9	(ICD9) UNSPECIFIED INTRACRANIAL HEMORRHAGE
459	(ICD9) HEMORRHAGE UNSPECIFIED
531	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE
531	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.01	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.2	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.4	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.4	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.41	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.6	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.61	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

Appendix A

532	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE
532	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.2	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.2	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.21	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.4	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.41	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.6	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.61	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.2	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.21	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.4	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.41	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.6	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.6	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.61	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION

Appendix A

534.01	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.2	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.2	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.21	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.4	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.41	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.6	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.6	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.61	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
578.1	(ICD9) BLOOD IN STOOL
719.1	(ICD9) HEMARTHROSIS
719.1	(ICD9) HEMARTHROSIS SITE UNSPECIFIED
719.11	(ICD9) HERARTHROSIS INVOLVING SHOULDER REGION
719.12	(ICD9) HEMARTHORSIS INVOLVING UPPER ARM
719.13	(ICD9) HEMARTHROSIS INVOLVING FOREARM
719.14	(ICD9) HEMARTHROSIS INVOLVING HAND
719.15	(ICD9) HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.16	(ICD9) HEMARTHROSIS INVOLVING LOWER LEG
719.17	(ICD9) HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.18	(ICD9) HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
719.19	(ICD9) HEMARTHROSIS INVOLVING MULTIPLE SITES
430	(ICD9) SUBARACHNOID HEMORRHAGE
431	(ICD9) INTRACEREBRAL HEMORRHAGE
I31.2	(ICD10) Hemopericardium, not elsewhere classified
I60.00	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01	(ICD10) Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.02	(ICD10) Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.11	(ICD10) Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.12	(ICD10) Nontraumatic subarachnoid hemorrhage from left middle cerebral artery

Appendix A

I60.2	(ICD10) Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.30	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.31	(ICD10) Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.32	(ICD10) Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.4	(ICD10) Nontraumatic subarachnoid hemorrhage from basilar artery
I60.50	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.51	(ICD10) Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.52	(ICD10) Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6	(ICD10) Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.7	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8	(ICD10) Other nontraumatic subarachnoid hemorrhage
I60.9	(ICD10) Nontraumatic subarachnoid hemorrhage, unspecified
I61.0	(ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.1	(ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.2	(ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3	(ICD10) Nontraumatic intracerebral hemorrhage in brain stem
I61.4	(ICD10) Nontraumatic intracerebral hemorrhage in cerebellum
I61.5	(ICD10) Nontraumatic intracerebral hemorrhage, intraventricular
I61.6	(ICD10) Nontraumatic intracerebral hemorrhage, multiple localized
I61.8	(ICD10) Other nontraumatic intracerebral hemorrhage
I61.9	(ICD10) Nontraumatic intracerebral hemorrhage, unspecified
I62.00	(ICD10) Nontraumatic subdural hemorrhage, unspecified
I62.01	(ICD10) Nontraumatic acute subdural hemorrhage
I62.02	(ICD10) Nontraumatic subacute subdural hemorrhage
I62.03	(ICD10) Nontraumatic chronic subdural hemorrhage
I62.1	(ICD10) Nontraumatic extradural hemorrhage
I62.9	(ICD10) Nontraumatic intracranial hemorrhage, unspecified
K25.0	(ICD10) Acute gastric ulcer with hemorrhage
K25.2	(ICD10) Acute gastric ulcer with both hemorrhage and perforation
K25.4	(ICD10) Chronic or unspecified gastric ulcer with hemorrhage
K25.6	(ICD10) Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0	(ICD10) Acute duodenal ulcer with hemorrhage
K26.2	(ICD10) Acute duodenal ulcer with both hemorrhage and perforation

Appendix A

K26.4	(ICD10) Chronic or unspecified duodenal ulcer with hemorrhage
K26.6	(ICD10) Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.0	(ICD10) Acute peptic ulcer, site unspecified, with hemorrhage
K27.2	(ICD10) Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.4	(ICD10) Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.6	(ICD10) Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0	(ICD10) Acute gastrojejunal ulcer with hemorrhage
K28.2	(ICD10) Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.4	(ICD10) Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6	(ICD10) Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K55.21	(ICD10) Angiodysplasia of colon with hemorrhage
K56.60	(ICD10) Unspecified intestinal obstruction
K57.01	(ICD10) Diverticulitis of small intestine with perforation and abscess with bleeding
K57.11	(ICD10) Diverticulosis of small intestine without perforation or abscess with bleeding
K57.13	(ICD10) Diverticulitis of small intestine without perforation or abscess with bleeding
K57.21	(ICD10) Diverticulitis of large intestine with perforation and abscess with bleeding
K57.31	(ICD10) Diverticulosis of large intestine without perforation or abscess with bleeding
K57.33	(ICD10) Diverticulitis of large intestine without perforation or abscess with bleeding
K57.41	(ICD10) Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.51	(ICD10) Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.53	(ICD10) Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.81	(ICD10) Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91	(ICD10) Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K57.93	(ICD10) Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5	(ICD10) Hemorrhage of anus and rectum
K63.1	(ICD10) Perforation of intestine (nontraumatic)
K63.81	(ICD10) Dieulafoy lesion of intestine
K66.1	(ICD10) Hemoperitoneum
K92.0	(ICD10) Hematemesis
K92.1	(ICD10) Melena
K92.2	(ICD10) Gastrointestinal hemorrhage, unspecified
M25.00	(ICD10) Hemarthrosis, unspecified joint
M25.011	(ICD10) Hemarthrosis, right shoulder

M25.012	(ICD10) Hemarthrosis, left shoulder
M25.019	(ICD10) Hemarthrosis, unspecified shoulder
M25.021	(ICD10) Hemarthrosis, right elbow
M25.022	(ICD10) Hemarthrosis, left elbow
M25.029	(ICD10) Hemarthrosis, unspecified elbow
M25.031	(ICD10) Hemarthrosis, right wrist
M25.032	(ICD10) Hemarthrosis, left wrist
M25.039	(ICD10) Hemarthrosis, unspecified wrist
M25.041	(ICD10) Hemarthrosis, right hand
M25.042	(ICD10) Hemarthrosis, left hand
M25.049	(ICD10) Hemarthrosis, unspecified hand
M25.051	(ICD10) Hemarthrosis, right hip
M25.052	(ICD10) Hemarthrosis, left hip
M25.059	(ICD10) Hemarthrosis, unspecified hip
M25.061	(ICD10) Hemarthrosis, right knee
M25.062	(ICD10) Hemarthrosis, left knee
M25.069	(ICD10) Hemarthrosis, unspecified knee
M25.071	(ICD10) Hemarthrosis, right ankle
M25.072	(ICD10) Hemarthrosis, left ankle
M25.073	(ICD10) Hemarthrosis, unspecified ankle
M25.074	(ICD10) Hemarthrosis, right foot
M25.075	(ICD10) Hemarthrosis, left foot
M25.076	(ICD10) Hemarthrosis, unspecified foot
M25.08	(ICD10) Hemarthrosis, other specified site
R58	(ICD10) Hemorrhage, not elsewhere classified
R04	(ICD10) Hemorrhage from respiratory passages
R04.0	(ICD10) Epistaxis
R04.1	(ICD10) Hemorrhage from throat
R04.2	(ICD10) Hemoptysis
R04.8	(ICD10) Hemorrhage from other sites in respiratory passages
R04.81	(ICD10) Acute idiopathic pulmonary hemorrhage in infants
R04.89	(ICD10) Hemorrhage from other sites in respiratory passages
R04.9	(ICD10) Hemorrhage from respiratory passages, unspecified

Appendix A

R31	(ICD10) Hematuria
R31.0	(ICD10) Gross hematuria
R31.1	(ICD10) Benign essential microscopic hematuria
R31.2	(ICD10) Other microscopic hematuria
R31.21	
R31.29	
R31.9	(ICD10) Hematuria, unspecified
784.7	(ICD9) EPISTAXIS
784.8	(ICD9) HEMORRHAGE FROM THROAT
599.7	(ICD9) HEMATURIA
599.7	(ICD9) HEMATURIA UNSPECIFIED
599.71	(ICD9) GROSS HEMATURIA
599.72	(ICD9) MICROSCOPIC HEMATURIA
786.3	(ICD9) HEMOPTYSIS
786.3	(ICD9) HEMOPTYSIS UNSPECIFIED
786.31	(ICD9) ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS
786.39	(ICD9) OTHER HEMOPTYSIS
The occurrence of Inpatient with the following attributes: **Procedure Code (Any Position) is any of: { "44.43", "43255", "0W3P8ZZ" }**	
44.43	(ICD9) ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING
43255	(HCPCS) Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method / Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with control of bleeding, any method
0W3P8ZZ	(ICD10) Control Bleeding in Gastrointestinal Tract, Via Natural or Artificial Opening Endoscopic

Appendix B

Optum	MarketScan

BEFORE PS MATCHING



Figure 63: Pre-matching propensity score overlap



Figure 63: Pre-matching propensity score overlap

The c-statistics for the propensity score model, pre-matching was 0.744. The post-matching c-statistic was 0.538.	The c-statistics for the propensity score model, pre-matching was 0.722. The post-matching c-statistic was 0.528.

AFTER PS MATCHING



Figure 64: Post-matching propensity score overlap



Figure 64: Post-matching propensity score overlap

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

	Unmatched								
	Optum			Truven			POOLED		
Variable	**Clopidogrel 75mg**	**Prasugrel 10mg**	**St. Diff.**	**Clopidogrel 75mg**	**Prasugrel 10mg**	**St. Diff.**	**Clopidogrel 75mg**	**Ticagrelor 90mg**	**St. Diff.**
Number of patients	**32,556**	**6,872**		**50,795**	**15,187**		**83,351**	**22,059**	
Age									
...mean (sd)	65.63 (12.12)	58.97 (10.27)	0.59	60.92 (11.98)	56.08 (8.96)	0.46	62.76 (12.03)	56.98 (9.39)	0.54
...median [IQR]	67.00 [57.00, 75.00]	59.00 [52.00, 67.00]	0.71	60.00 [53.00, 68.00]	57.00 [50.00, 62.00]	0.28	62.73 (12.03)	57.62 (9.39)	0.47
Age categories									
...18 - 54; n (%)	6,488 (19.9%)	2,342 (34.1%)	-0.32	15,420 (30.4%)	6,296 (41.5%)	-0.23	21,908 (26.3%)	8,638 (39.2%)	-0.28
...55 - 64; n (%)	7,900 (24.3%)	2,300 (33.5%)	-0.20	19,596 (38.6%)	6,745 (44.4%)	-0.12	27,496 (33.0%)	9,045 (41.0%)	-0.17
...65 - 74; n (%)	9,646 (29.6%)	1,861 (27.1%)	0.06	7,876 (15.5%)	1,834 (12.1%)	0.10	17,522 (21.0%)	3,695 (16.8%)	0.11
...>= 75; n (%)	8,522 (26.2%)	369 (5.4%)	0.59	7,903 (15.6%)	312 (2.1%)	0.49	16,425 (19.7%)	0,681 (3.1%)	0.54
Gender- United									
...Males; n (%)	21,743 (66.8%)	5,279 (76.8%)	-0.22	36,413 (71.7%)	12,111 (79.7%)	-0.19	58,156 (69.8%)	17,390 (78.8%)	-0.21
...Females; n (%)	10,813 (33.2%)	1,593 (23.2%)	0.22	14,382 (28.3%)	3,076 (20.3%)	0.19	25,195 (30.2%)	4,669 (21.2%)	0.21
Region									
...Northeast; n (%)	3,792 (11.6%)	520 (7.6%)	0.14	9,397 (18.5%)	2,412 (15.9%)	0.07	13,189 (15.8%)	2,932 (13.3%)	0.07
...South; n (%)	13,415 (41.2%)	3,530 (51.4%)	-0.21	15,086 (29.7%)	3,797 (25.0%)	0.11	28,501 (34.2%)	7,327 (33.2%)	0.02
...Midwest; n (%)	9,686 (29.8%)	1,655 (24.1%)	0.13	17,860 (35.2%)	6,576 (43.3%)	-0.17	27,546 (33.0%)	8,231 (37.3%)	-0.09
...West; n (%)	5,663 (17.4%)	1,167 (17.0%)	0.01	7,896 (15.5%)	2,181 (14.4%)	0.03	13,559 (16.3%)	3,348 (15.2%)	0.03
...Unknown+missing; n (%)	N/A	N/A	#VALUE!	556 (1.1%)	221 (1.5%)	-0.04	556 (0.7%)	221 (1.0%)	-0.03
CV Covariates									
Ischemic heart disease; n (%)	32,556 (100.0%)	6,872 (100.0%)	#DIV/0!	50,795 (100.0%)	15,187 (100.0%)	#DIV/0!	83,351 (100.0%)	22,059 (100.0%)	#DIV/0!
Acute MI; n (%)	30,440 (93.5%)	6,584 (95.8%)	-0.10	49,272 (97.0%)	14,846 (97.8%)	-0.05	79712 (95.6%)	21430 (97.1%)	-0.08
ACS/unstable angina; n (%)	13,130 (40.3%)	2,491 (36.2%)	0.08	16,600 (32.7%)	4,707 (31.0%)	0.04	29730 (35.7%)	7198 (32.6%)	0.07
Old MI; n (%)	4,370 (13.4%)	739 (10.8%)	0.08	3,850 (7.6%)	1,014 (6.7%)	0.03	8220 (9.9%)	1753 (7.9%)	0.07
Stable angina; n (%)	6,311 (19.4%)	1,068 (15.5%)	0.10	5,813 (11.4%)	1,663 (11.0%)	0.01	12,124 (14.5%)	2,731 (12.4%)	0.06
Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)	31,630 (97.2%)	6,662 (96.9%)	0.02	46,490 (91.5%)	13,861 (91.3%)	0.01	78,120 (93.7%)	20,523 (93.0%)	0.03
Other atherosclerosis with ICD10 ; n (%)	560 (1.7%)	97 (1.4%)	0.02	782 (1.5%)	157 (1.0%)	0.05	1342 (1.6%)	254 (1.2%)	0.03
Previous cardiac procedure (CABG or PTCA or Stent) ; n (%)	31,882 (97.9%)	6,786 (98.7%)	-0.06	49,694 (97.8%)	14,936 (98.3%)	-0.04	81576 (97.9%)	21722 (98.5%)	-0.05
History of CABG or PTCA; n (%)	9,533 (29.3%)	1,631 (23.7%)	0.13	7,438 (14.6%)	1,995 (13.1%)	0.04	16,971 (20.4%)	3,626 (16.4%)	0.10
Any stroke; n (%)	2,400 (7.4%)	287 (4.2%)	0.14	2,470 (4.9%)	390 (2.6%)	0.12	4,870 (5.8%)	0,677 (3.1%)	0.13
Ischemic stroke (w and w/o mention of cerebral infarction); n (%)	2,399 (7.4%)	287 (4.2%)	0.14	2,470 (4.9%)	390 (2.6%)	0.12	4,869 (5.8%)	0,677 (3.1%)	0.13
Hemorrhagic stroke; n (%)	1 (0.0%)	0 (0.0%)	#DIV/0!	1 (0.0%)	0 (0.0%)	#DIV/0!	2 (0.0%)	0 (0.0%)	#DIV/0!
TIA; n (%)	480 (1.5%)	46 (0.7%)	0.08	523 (1.0%)	63 (0.4%)	0.07	1003 (1.2%)	109 (0.5%)	0.08
Other cerebrovascular disease; n (%)	450 (1.4%)	43 (0.6%)	0.08	388 (0.8%)	46 (0.3%)	0.07	838 (1.0%)	89 (0.4%)	0.07
Late effects of cerebrovascular disease; n (%)	396 (1.2%)	28 (0.4%)	0.09	291 (0.6%)	21 (0.1%)	0.08	687 (0.8%)	49 (0.2%)	0.09
Cerebrovascular procedure; n (%)	16 (0.0%)	1 (0.0%)	#DIV/0!	34 (0.1%)	1 (0.0%)	0.04	50 (0.1%)	2 (0.0%)	0.04
Heart failure (CHF); n (%)	6,838 (21.0%)	941 (13.7%)	0.19	7,137 (14.1%)	1,632 (10.7%)	0.10	13,975 (16.8%)	2,573 (11.7%)	0.15
Peripheral Vascular Disease (PVD) or PVD Surgery ; n (%)	2,702 (8.3%)	361 (5.3%)	0.12	2,268 (4.5%)	413 (2.7%)	0.10	4,970 (6.0%)	0,774 (3.5%)	0.12

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Atrial fibrillation; n (%)	4,283 (13.2%)	413 (6.0%)	0.25	4,104 (8.1%)	574 (3.8%)	0.18	8,387 (10.1%)	0,987 (4.5%)	0.22
Other cardiac dysrhythmia; n (%)	9,981 (30.7%)	1,632 (23.7%)	0.16	10,768 (21.2%)	2,653 (17.5%)	0.09	20,749 (24.9%)	4,285 (19.4%)	0.13
Cardiac conduction disorders; n (%)	4,606 (14.1%)	639 (9.3%)	0.15	4,344 (8.6%)	958 (6.3%)	0.09	8950 (10.7%)	1597 (7.2%)	0.12
Other CVD; n (%)	11,182 (34.3%)	1,890 (27.5%)	0.15	12,049 (23.7%)	3,160 (20.8%)	0.07	23,231 (27.9%)	5,050 (22.9%)	0.12
Diabetes-related complications									
Diabetic retinopathy; n (%)	742 (2.3%)	140 (2.0%)	0.02	641 (1.3%)	152 (1.0%)	0.03	1,383 (1.7%)	0,292 (1.3%)	0.03
Diabetes with other ophthalmic manifestations; n (%)	61 (0.2%)	6 (0.1%)	0.03	426 (0.8%)	109 (0.7%)	0.01	0,487 (0.6%)	0,115 (0.5%)	0.01
Retinal detachment, vitreous hemorrhage, vitrectomy; n (%)	15 (0.0%)	1 (0.0%)	#DIV/0!	15 (0.0%)	4 (0.0%)	#DIV/0!	30 (0.0%)	5 (0.0%)	#DIV/0!
Retinal laser coagulation therapy; n (%)	63 (0.2%)	11 (0.2%)	0.00	103 (0.2%)	28 (0.2%)	0.00	166 (0.2%)	39 (0.2%)	0.00
Occurrence of Diabetic Neuropathy ; n (%)	2,028 (6.2%)	331 (4.8%)	0.06	1,485 (2.9%)	353 (2.3%)	0.04	3,513 (4.2%)	0,684 (3.1%)	0.06
Occurrence of diabetic nephropathy with ICD10 ; n (%)	1,915 (5.9%)	238 (3.5%)	0.11	994 (2.0%)	203 (1.3%)	0.05	2,909 (3.5%)	0,441 (2.0%)	0.09
Hypoglycemia ; n (%)	396 (1.2%)	71 (1.0%)	0.02	608 (1.2%)	138 (0.9%)	0.03	1,004 (1.2%)	0,209 (0.9%)	0.03
Hyperglycemia; n (%)	2,444 (7.5%)	521 (7.6%)	0.00	2,152 (4.2%)	697 (4.6%)	-0.02	4,596 (5.5%)	1,218 (5.5%)	0.00
Disorders of fluid electrolyte and acid-base balance; n (%)	4,694 (14.4%)	808 (11.8%)	0.08	4,163 (8.2%)	1,078 (7.1%)	0.04	8,857 (10.6%)	1,886 (8.5%)	0.07
Diabetic ketoacidosis; n (%)	127 (0.4%)	22 (0.3%)	0.02	182 (0.4%)	53 (0.3%)	0.02	309 (0.4%)	75 (0.3%)	0.02
Hyperosmolar hyperglycemic nonketotic syndrome (HONK); n (%)	81 (0.2%)	18 (0.3%)	-0.02	54 (0.1%)	14 (0.1%)	0.00	135 (0.2%)	32 (0.1%)	0.03
Diabetes with peripheral circulatory disorders with ICD-10 ; n (%)	946 (2.9%)	101 (1.5%)	0.10	537 (1.1%)	126 (0.8%)	0.03	1,483 (1.8%)	0,227 (1.0%)	0.07
Diabetic Foot; n (%)	374 (1.1%)	54 (0.8%)	0.03	378 (0.7%)	92 (0.6%)	0.01	752 (0.9%)	146 (0.7%)	0.02
Gangrene ; n (%)	39 (0.1%)	4 (0.1%)	0.00	30 (0.1%)	9 (0.1%)	0.00	69 (0.1%)	13 (0.1%)	0.00
Lower extremity amputation; n (%)	145 (0.4%)	22 (0.3%)	0.02	67 (0.1%)	23 (0.2%)	-0.03	212 (0.3%)	45 (0.2%)	0.02
Osteomyelitis; n (%)	99 (0.3%)	16 (0.2%)	0.02	110 (0.2%)	21 (0.1%)	0.03	209 (0.3%)	37 (0.2%)	0.02
Skin infections ; n (%)	1,316 (4.0%)	240 (3.5%)	0.03	1,628 (3.2%)	437 (2.9%)	0.02	2,944 (3.5%)	0,677 (3.1%)	0.02
Erectile dysfunction; n (%)	856 (2.6%)	240 (3.5%)	-0.05	1,014 (2.0%)	329 (2.2%)	-0.01	1,870 (2.2%)	0,569 (2.6%)	-0.03
Diabetes with unspecified complication; n (%)	759 (2.3%)	148 (2.2%)	0.01	696 (1.4%)	246 (1.6%)	-0.02	1,455 (1.7%)	0,394 (1.8%)	-0.01
Diabetes mellitus without mention of complications; n (%)	10,901 (33.5%)	2,146 (31.2%)	0.05	13,531 (26.6%)	3,957 (26.1%)	0.01	24,432 (29.3%)	6,103 (27.7%)	0.04
Hypertension: 1 inpatient or 2 outpatient claims within 365 days; n (%)	26,001 (79.9%)	5,031 (73.2%)	0.16	33,778 (66.5%)	9,642 (63.5%)	0.06	59,779 (71.7%)	14,673 (66.5%)	0.11
Hyperlipidemia ; n (%)	26,353 (80.9%)	5,585 (81.3%)	-0.01	32,023 (63.0%)	10,002 (65.9%)	-0.06	58,376 (70.0%)	15,587 (70.7%)	-0.02
Edema; n (%)	1,711 (5.3%)	184 (2.7%)	0.13	1,267 (2.5%)	262 (1.7%)	0.06	2,978 (3.6%)	0,446 (2.0%)	0.10
Renal Dysfunction (non-diabetic) ; n (%)	6,929 (21.3%)	936 (13.6%)	0.20	5,898 (11.6%)	1,168 (7.7%)	0.13	12,827 (15.4%)	2,104 (9.5%)	0.18
Occurrence of acute renal disease ; n (%)	2,912 (8.9%)	403 (5.9%)	0.11	2,293 (4.5%)	488 (3.2%)	0.07	5205 (6.2%)	891 (4.0%)	0.10
Occurrence of chronic renal insufficiency; n (%)	4,727 (14.5%)	549 (8.0%)	0.21	3,259 (6.4%)	558 (3.7%)	0.12	7,986 (9.6%)	1,107 (5.0%)	0.18
Chronic kidney disease ; n (%)	4,603 (14.1%)	526 (7.7%)	0.21	3,172 (6.2%)	537 (3.5%)	0.13	7,775 (9.3%)	1,063 (4.8%)	0.18
CKD Stage 3-4; n (%)	2,896 (8.9%)	296 (4.3%)	0.19	1,875 (3.7%)	284 (1.9%)	0.11	4,771 (5.7%)	0,580 (2.6%)	0.16

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of hypertensive nephropathy; n (%)	3,749 (11.5%)	412 (6.0%)	0.20	2,431 (4.8%)	415 (2.7%)	0.11	6180 (7.4%)	827 (3.7%)	0.16
Occurrence of miscellaneous renal insufficiency ; n (%)	2,374 (7.3%)	359 (5.2%)	0.09	1,923 (3.8%)	418 (2.8%)	0.06	4,297 (5.2%)	0,777 (3.5%)	0.08
Glaucoma or cataracts ; n (%)	4,247 (13.0%)	576 (8.4%)	0.15	4,713 (9.3%)	902 (5.9%)	0.13	8,960 (10.7%)	1,478 (6.7%)	0.14
Cellulitis or abscess of toe; n (%)	276 (0.8%)	33 (0.5%)	0.04	173 (0.3%)	48 (0.3%)	0.00	449 (0.5%)	81 (0.4%)	0.01
Foot ulcer; n (%)	376 (1.2%)	52 (0.8%)	0.04	379 (0.7%)	92 (0.6%)	0.01	755 (0.9%)	144 (0.7%)	0.02
Bladder stones; n (%)	57 (0.2%)	7 (0.1%)	0.03	48 (0.1%)	8 (0.1%)	0.00	105 (0.1%)	15 (0.1%)	0.00
Kidney stones; n (%)	729 (2.2%)	143 (2.1%)	0.01	857 (1.7%)	258 (1.7%)	0.00	1,586 (1.9%)	0,401 (1.8%)	0.01
Urinary tract infections (UTIs); n (%)	2,281 (7.0%)	303 (4.4%)	0.11	2,080 (4.1%)	441 (2.9%)	0.07	4,361 (5.2%)	0,744 (3.4%)	0.09
Dipstick urinalysis; n (%)	7,433 (22.8%)	1,375 (20.0%)	0.07	10,098 (19.9%)	3,062 (20.2%)	-0.01	17,531 (21.0%)	4,437 (20.1%)	0.02
Non-dipstick urinalysis; n (%)	3,761 (11.6%)	666 (9.7%)	0.06	3,775 (7.4%)	1,224 (8.1%)	-0.03	7,536 (9.0%)	1,890 (8.6%)	0.01
Urine function test; n (%)	682 (2.1%)	108 (1.6%)	0.04	934 (1.8%)	189 (1.2%)	0.05	1,616 (1.9%)	0,297 (1.3%)	0.05
Cytology; n (%)	332 (1.0%)	45 (0.7%)	0.03	497 (1.0%)	87 (0.6%)	0.04	829 (1.0%)	132 (0.6%)	0.04
Cystos; n (%)	468 (1.4%)	61 (0.9%)	0.05	640 (1.3%)	113 (0.7%)	0.06	1108 (1.3%)	174 (0.8%)	0.05
Other Covariates									
Liver disease; n (%)	11 (0.0%)	2 (0.0%)	#DIV/0!	9 (0.0%)	6 (0.0%)	#DIV/0!	0,020 (0.0%)	0,008 (0.0%)	#DIV/0!
Osteoarthritis; n (%)	5,215 (16.0%)	796 (11.6%)	0.13	4,978 (9.8%)	1,170 (7.7%)	0.07	10,193 (12.2%)	1,966 (8.9%)	0.11
Other arthritis, arthropathies and musculoskeletal pain; n (%)	11,251 (34.6%)	2,072 (30.2%)	0.09	13,878 (27.3%)	3,718 (24.5%)	0.06	25,129 (30.1%)	5,790 (26.2%)	0.09
Dorsopathies; n (%)	7,629 (23.4%)	1,462 (21.3%)	0.05	9,142 (18.0%)	2,497 (16.4%)	0.04	16,771 (20.1%)	3,959 (17.9%)	0.06
Fractures; n (%)	758 (2.3%)	116 (1.7%)	0.04	879 (1.7%)	209 (1.4%)	0.02	1,637 (2.0%)	0,325 (1.5%)	0.04
Falls ; n (%)	742 (2.3%)	85 (1.2%)	0.08	316 (0.6%)	54 (0.4%)	0.03	1058 (1.3%)	139 (0.6%)	0.07
Osteoporosis; n (%)	1,494 (4.6%)	137 (2.0%)	0.15	1,313 (2.6%)	149 (1.0%)	0.12	2,807 (3.4%)	0,286 (1.3%)	0.14
Hyperthyroidism; n (%)	181 (0.6%)	34 (0.5%)	0.01	189 (0.4%)	37 (0.2%)	0.04	370 (0.4%)	71 (0.3%)	0.02
Hypothyroidism ; n (%)	4,397 (13.5%)	682 (9.9%)	0.11	4,244 (8.4%)	992 (6.5%)	0.07	8,641 (10.4%)	1,674 (7.6%)	0.10
Other disorders of thyroid gland ; n (%)	750 (2.3%)	131 (1.9%)	0.03	867 (1.7%)	225 (1.5%)	0.02	1,617 (1.9%)	0,356 (1.6%)	0.02
Depression; n (%)	3,047 (9.4%)	634 (9.2%)	0.01	3,332 (6.6%)	907 (6.0%)	0.02	6,379 (7.7%)	1,541 (7.0%)	0.03
Anxiety; n (%)	3,443 (10.6%)	720 (10.5%)	0.00	3,184 (6.3%)	1,000 (6.6%)	-0.01	6,627 (8.0%)	1,720 (7.8%)	0.01
Sleep_Disorder; n (%)	2,282 (7.0%)	594 (8.6%)	-0.06	3,772 (7.4%)	1,215 (8.0%)	-0.02	6,054 (7.3%)	1,809 (8.2%)	-0.03
Dementia; n (%)	487 (1.5%)	22 (0.3%)	0.13	413 (0.8%)	38 (0.3%)	0.07	900 (1.1%)	60 (0.3%)	0.10
Delirium; n (%)	197 (0.6%)	20 (0.3%)	0.04	147 (0.3%)	23 (0.2%)	0.02	344 (0.4%)	43 (0.2%)	0.04
Psychosis; n (%)	19 (0.1%)	2 (0.0%)	0.04	16 (0.0%)	2 (0.0%)	#DIV/0!	35 (0.0%)	4 (0.0%)	#DIV/0!
Obesity; n (%)	6,887 (21.2%)	1,604 (23.3%)	-0.05	7,002 (13.8%)	2,329 (15.3%)	-0.04	13,889 (16.7%)	3,933 (17.8%)	-0.03
Overweight; n (%)	1,386 (4.3%)	255 (3.7%)	0.03	816 (1.6%)	259 (1.7%)	-0.01	2,202 (2.6%)	0,514 (2.3%)	0.02
Smoking; n (%)	14,928 (45.9%)	3,204 (46.6%)	-0.01	15,361 (30.2%)	4,812 (31.7%)	-0.03	30,289 (36.3%)	8,016 (36.3%)	0.00
Alcohol abuse or dependence; n (%)	4 (0.0%)	0 (0.0%)	#DIV/0!	504 (1.0%)	170 (1.1%)	-0.01	508 (0.6%)	170 (0.8%)	-0.02
Drug abuse or dependence; n (%)	8 (0.0%)	2 (0.0%)	#DIV/0!	2 (0.0%)	0 (0.0%)	#DIV/0!	10 (0.0%)	2 (0.0%)	#DIV/0!
COPD; n (%)	5,055 (15.5%)	674 (9.8%)	0.17	4,803 (9.5%)	964 (6.3%)	0.12	9,858 (11.8%)	1,638 (7.4%)	0.15
Asthma; n (%)	2,227 (6.8%)	403 (5.9%)	0.04	2,515 (5.0%)	621 (4.1%)	0.04	4,742 (5.7%)	1,024 (4.6%)	0.05
Obstructive sleep apnea; n (%)	2,734 (8.4%)	634 (9.2%)	-0.03	3,200 (6.3%)	1,045 (6.9%)	-0.02	5,934 (7.1%)	1,679 (7.6%)	-0.02
Pneumonia; n (%)	1,627 (5.0%)	238 (3.5%)	0.07	1,716 (3.4%)	358 (2.4%)	0.06	3,343 (4.0%)	0,596 (2.7%)	0.07
Imaging; n (%)	698 (2.1%)	132 (1.9%)	0.01	4,713 (9.3%)	133 (0.9%)	0.39	1138 (1.4%)	265 (1.2%)	0.02
Other Medications									
Use of ACE inhibitors; n (%)	17,584 (54.0%)	3,742 (54.5%)	-0.01	29,471 (58.0%)	9,091 (59.9%)	-0.04	47,055 (56.5%)	12,833 (58.2%)	-0.03
Use of ARBs; n (%)	5,799 (17.8%)	1,182 (17.2%)	0.02	8,108 (16.0%)	2,346 (15.4%)	0.02	13,907 (16.7%)	3,528 (16.0%)	0.02
Use of Loop Diuretics - United; n (%)	3,974 (12.2%)	449 (6.5%)	0.20	4,290 (8.4%)	720 (4.7%)	0.15	8,264 (9.9%)	1,169 (5.3%)	0.17
Use of other diuretics- United; n (%)	1,162 (3.6%)	249 (3.6%)	0.00	1,686 (3.3%)	520 (3.4%)	-0.01	2,848 (3.4%)	0,769 (3.5%)	-0.01

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Use of nitrates-United; n (%)	14,693 (45.1%)	2,981 (43.4%)	0.03	24,231 (47.7%)	6,928 (45.6%)	0.04	38,924 (46.7%)	9,909 (44.9%)	0.04
Use of other hypertension drugs; n (%)	2,065 (6.3%)	271 (3.9%)	0.11	2,486 (4.9%)	513 (3.4%)	0.08	4,551 (5.5%)	0,784 (3.6%)	0.09
Use of digoxin- United; n (%)	517 (1.6%)	49 (0.7%)	0.08	749 (1.5%)	94 (0.6%)	0.09	1266 (1.5%)	143 (0.6%)	0.09
Use of Anti-arrhythmics; n (%)	897 (2.8%)	88 (1.3%)	0.11	1,065 (2.1%)	171 (1.1%)	0.08	1962 (2.4%)	259 (1.2%)	0.09
Use of COPD/asthma meds- United; n (%)	4,160 (12.8%)	750 (10.9%)	0.06	6,088 (12.0%)	1,656 (10.9%)	0.03	10,248 (12.3%)	2,406 (10.9%)	0.04
Use of statins; n (%)	29,217 (89.7%)	6,272 (91.3%)	-0.05	45,797 (90.2%)	13,815 (91.0%)	-0.03	75,014 (90.0%)	20,087 (91.1%)	-0.04
Use of other lipid-lowering drugs; n (%)	2,494 (7.7%)	609 (8.9%)	-0.04	4,655 (9.2%)	1,435 (9.4%)	-0.01	7,149 (8.6%)	2,044 (9.3%)	-0.02
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Warfarin); n (%)	2,662 (8.2%)	171 (2.5%)	0.26	3,286 (6.5%)	393 (2.6%)	0.19	5,948 (7.1%)	0,564 (2.6%)	0.21
Use of heparin and other low-molecular weight heparins; n (%)	330 (1.0%)	29 (0.4%)	0.07	2 (0.0%)	3 (0.0%)	#DIV/0!	332 (0.4%)	32 (0.1%)	0.06
Use of NSAIDs; n (%)	4,155 (12.8%)	898 (13.1%)	-0.01	6,384 (12.6%)	1,965 (12.9%)	-0.01	10,539 (12.6%)	2,863 (13.0%)	-0.01
Use of oral corticosteroids; n (%)	5,465 (16.8%)	953 (13.9%)	0.08	7,355 (14.5%)	2,031 (13.4%)	0.03	12,820 (15.4%)	2,984 (13.5%)	0.05
Use of bisphosphonate (United); n (%)	604 (1.9%)	58 (0.8%)	0.10	773 (1.5%)	82 (0.5%)	0.10	1377 (1.7%)	140 (0.6%)	0.10
Use of opioids- United; n (%)	7,601 (23.3%)	1,567 (22.8%)	0.01	11,530 (22.7%)	3,264 (21.5%)	0.03	19,131 (23.0%)	4,831 (21.9%)	0.03
Use of antidepressants; n (%)	5,200 (16.0%)	1,058 (15.4%)	0.02	7,509 (14.8%)	2,093 (13.8%)	0.03	12,709 (15.2%)	3,151 (14.3%)	0.03
Use of antipsychotics; n (%)	292 (0.9%)	44 (0.6%)	0.03	396 (0.8%)	108 (0.7%)	0.01	0,688 (0.8%)	0,152 (0.7%)	0.01
Use of anticonvulsants; n (%)	3,010 (9.2%)	498 (7.2%)	0.07	3,327 (6.5%)	789 (5.2%)	0.06	6,337 (7.6%)	1,287 (5.8%)	0.07
Use of lithium- United; n (%)	31 (0.1%)	7 (0.1%)	0.00	60 (0.1%)	17 (0.1%)	0.00	91 (0.1%)	24 (0.1%)	0.00
Use of Benzos- United; n (%)	2,919 (9.0%)	668 (9.7%)	-0.02	5,195 (10.2%)	1,421 (9.4%)	0.03	8,114 (9.7%)	2,089 (9.5%)	0.01
Use of anxiolytics/hypnotics- United; n (%)	1,506 (4.6%)	352 (5.1%)	-0.02	2,651 (5.2%)	818 (5.4%)	-0.01	4,157 (5.0%)	1,170 (5.3%)	-0.01
Use of dementia meds- United; n (%)	178 (0.5%)	14 (0.2%)	0.05	252 (0.5%)	13 (0.1%)	0.07	430 (0.5%)	27 (0.1%)	0.07
Use of antiparkinsonian meds- United; n (%)	547 (1.7%)	63 (0.9%)	0.07	652 (1.3%)	118 (0.8%)	0.05	1,199 (1.4%)	0,181 (0.8%)	0.06
Entresto (sacubitril/valsartan); n (%)	22 (0.1%)	2 (0.0%)	0.04	3 (0.0%)	2 (0.0%)	#DIV/0!	25 (0.0%)	4 (0.0%)	#DIV/0!
Labs							0	0	
Lab values- HbA1c (%) ; n (%)	3,678 (11.3%)	668 (9.7%)	0.05	559 (1.1%)	130 (0.9%)	0.02	4,237 (5.1%)	0,798 (3.6%)	0.07
Lab values- HbA1c (%) (within 3 months) ; n (%)	2,396 (7.4%)	415 (6.0%)	0.06	395 (0.8%)	79 (0.5%)	0.04	2,791 (3.3%)	0,494 (2.2%)	0.07
Lab values- HbA1c (%) (within 6 months) ; n (%)	3,678 (11.3%)	668 (9.7%)	0.05	559 (1.1%)	130 (0.9%)	0.02	4,237 (5.1%)	0,798 (3.6%)	0.07
Lab values- BNP; n (%)	257 (0.8%)	31 (0.5%)	0.04	41 (0.1%)	6 (0.0%)	0.04	298 (0.4%)	37 (0.2%)	0.04
Lab values- BNP (within 3 months); n (%)	200 (0.6%)	26 (0.4%)	0.03	37 (0.1%)	5 (0.0%)	0.04	237 (0.3%)	31 (0.1%)	0.04
Lab values- BNP (within 6 months); n (%)	257 (0.8%)	31 (0.5%)	0.04	41 (0.1%)	6 (0.0%)	0.04	298 (0.4%)	37 (0.2%)	0.04
Lab values- BUN (mg/dl); n (%)	6,259 (19.2%)	1,248 (18.2%)	0.03	444 (0.9%)	144 (0.9%)	0.00	6,703 (8.0%)	1,392 (6.3%)	0.07
Lab values- BUN (mg/dl) (within 3 months); n (%)	4,032 (12.4%)	755 (11.0%)	0.04	306 (0.6%)	95 (0.6%)	0.00	4,338 (5.2%)	0,850 (3.9%)	0.06
Lab values- BUN (mg/dl) (within 6 months); n (%)	6,259 (19.2%)	1,248 (18.2%)	0.03	444 (0.9%)	144 (0.9%)	0.00	6,703 (8.0%)	1,392 (6.3%)	0.07
Lab values- Creatinine (mg/dl) ; n (%)	6,410 (19.7%)	1,279 (18.6%)	0.03	467 (0.9%)	153 (1.0%)	-0.01	6,877 (8.3%)	1,432 (6.5%)	0.07
Lab values- Creatinine (mg/dl) (within 3 months) ; n (%)	4,139 (12.7%)	775 (11.3%)	0.04	317 (0.6%)	100 (0.7%)	-0.01	4,456 (5.3%)	0,875 (4.0%)	0.06

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Lab values- Creatinine (mg/dl) (within 6 months) ; n (%)	6,410 (19.7%)	1,279 (18.6%)	0.03	467 (0.9%)	153 (1.0%)	-0.01	6,877 (8.3%)	1,432 (6.5%)	0.07
Lab values- HDL level (mg/dl); n (%)	4,980 (15.3%)	1,064 (15.5%)	-0.01	506 (1.0%)	130 (0.9%)	0.01	5,486 (6.6%)	1,194 (5.4%)	0.05
Lab values- HDL level (mg/dl) (within 3 months); n (%)	3,015 (9.3%)	623 (9.1%)	0.01	333 (0.7%)	85 (0.6%)	0.01	3,348 (4.0%)	0,708 (3.2%)	0.04
Lab values- HDL level (mg/dl) (within 6 months); n (%)	4,980 (15.3%)	1,064 (15.5%)	-0.01	506 (1.0%)	130 (0.9%)	0.01	5,486 (6.6%)	1,194 (5.4%)	0.05
Lab values- LDL level (mg/dl) ; n (%)	5,080 (15.6%)	1,074 (15.6%)	0.00	571 (1.1%)	135 (0.9%)	0.02	5,651 (6.8%)	1,209 (5.5%)	0.05
Lab values- LDL level (mg/dl) (within 3 months) ; n (%)	3,064 (9.4%)	626 (9.1%)	0.01	400 (0.8%)	87 (0.6%)	0.02	3,464 (4.2%)	0,713 (3.2%)	0.05
Lab values- LDL level (mg/dl) (within 6 months) ; n (%)	5,080 (15.6%)	1,074 (15.6%)	0.00	571 (1.1%)	135 (0.9%)	0.02	5,651 (6.8%)	1,209 (5.5%)	0.05
Lab values- NT-proBNP; n (%)	36 (0.1%)	7 (0.1%)	0.00	1 (0.0%)	0 (0.0%)	#DIV/0!	37 (0.0%)	7 (0.0%)	#DIV/0!
Lab values- NT-proBNP (within 3 months); n (%)	28 (0.1%)	6 (0.1%)	0.00	1 (0.0%)	0 (0.0%)	#DIV/0!	29 (0.0%)	6 (0.0%)	#DIV/0!
Lab values- NT-proBNP (within 6 months); n (%)	36 (0.1%)	7 (0.1%)	0.00	1 (0.0%)	0 (0.0%)	#DIV/0!	37 (0.0%)	7 (0.0%)	#DIV/0!
Lab values- Total cholesterol (mg/dl) ; n (%)	5,029 (15.4%)	1,068 (15.5%)	0.00	510 (1.0%)	131 (0.9%)	0.01	5,539 (6.6%)	1,199 (5.4%)	0.05
Lab values- Total cholesterol (mg/dl) (within 3 months) ; n (%)	3,031 (9.3%)	621 (9.0%)	0.01	339 (0.7%)	85 (0.6%)	0.01	3,370 (4.0%)	0,706 (3.2%)	0.04
Lab values- Total cholesterol (mg/dl) (within 6 months) ; n (%)	5,029 (15.4%)	1,068 (15.5%)	0.00	510 (1.0%)	131 (0.9%)	0.01	5,539 (6.6%)	1,199 (5.4%)	0.05
Lab values- Triglyceride level (mg/dl); n (%)	4,942 (15.2%)	1,070 (15.6%)	-0.01	497 (1.0%)	129 (0.8%)	0.02	5,439 (6.5%)	1,199 (5.4%)	0.05
Lab values- Triglyceride level (mg/dl) (within 3 months); n (%)	2,969 (9.1%)	623 (9.1%)	0.00	325 (0.6%)	84 (0.6%)	0.00	3,294 (4.0%)	0,707 (3.2%)	0.04
Lab values- Triglyceride level (mg/dl) (within 6 months); n (%)	4,942 (15.2%)	1,070 (15.6%)	-0.01	497 (1.0%)	129 (0.8%)	0.02	5,439 (6.5%)	1,199 (5.4%)	0.05
Lab result number- HbA1c (%) mean (only 2 to 20 included)	3,659	664		434	118		0	0	
...mean (sd)	7.12 (1.74)	7.18 (1.76)	-0.03	8.08 (1.93)	8.20 (1.99)	-0.06	7.71 (1.86)	7.88 (1.92)	-0.09
...median [IQR]	6.60 [5.90, 7.80]	6.60 [5.90, 8.00]	0.00	7.57 [6.70, 9.20]	7.60 [6.80, 9.42]	-0.02	7.19 (1.86)	7.29 (1.92)	-0.05
...Missing; n (%)	28,897 (88.8%)	6,208 (90.3%)	-0.05	50,361 (99.1%)	15,069 (99.2%)	-0.01	79,258 (95.1%)	21,277 (96.5%)	-0.07
Lab result number- BNP mean	257	31		41	6		0	0	
...mean (sd)	286.40 (807.84)	181.63 (295.19)	0.17	462.66 (983.56)	98.17 (120.28)	0.52	393.81 (918.93)	124.17 (192.63)	0.41
...median [IQR]	100.00 [36.25, 242.10]	66.10 [31.00, 164.33]	0.06	159.00 [30.50, 397.00]	55.00 [30.75, 161.50]	0.15	135.96 (918.93)	58.46 (192.63)	0.12
...Missing; n (%)	32,299 (99.2%)	6,841 (99.5%)	-0.04	50,754 (99.9%)	15,181 (100.0%)	-0.04	83,053 (99.6%)	22,022 (99.8%)	-0.04
Lab result number- BUN (mg/dl) mean	6,259	1,248		444	144		0	0	
...mean (sd)	18.65 (8.48)	17.48 (7.01)	0.15	333.36 (6,643.25)	1,684.66 (14,140.00)	-0.12	210.44 (5186.05)	1165.29 (11732.70)	-0.11
...median [IQR]	17.00 [14.00, 21.50]	16.00 [13.00, 20.00]	0.13	16.00 [13.50, 20.50]	16.33 [13.00, 21.00]	0.00	16.39 (5186.05)	16.23 (11732.70)	0.00
...Missing; n (%)	26,297 (80.8%)	5,624 (81.8%)	-0.03	50,351 (99.1%)	15,043 (99.1%)	0.00	76,648 (92.0%)	20,667 (93.7%)	-0.07
Lab result number- Creatinine (mg/dl) mean (only 0.1 to 15 included)	6,323	1,270		426	137		0	0	
...mean (sd)	1.09 (0.54)	1.04 (0.43)	0.10	1.04 (0.77)	1.06 (0.53)	-0.03	1.06 (0.69)	1.05 (0.50)	0.02
...median [IQR]	0.99 [0.84, 1.18]	0.98 [0.83, 1.14]	0.02	0.95 [0.82, 1.09]	1.00 [0.82, 1.19]	-0.08	0.97 (0.69)	0.99 (0.50)	-0.03

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)	26,233 (80.6%)	5,602 (81.5%)	-0.02	50,369 (99.2%)	15,050 (99.1%)	0.01	76,602 (91.9%)	20,652 (93.6%)	-0.07
Lab result number- HDL level (mg/dl) mean (only =<5000 included)	4,980	1,064		505	128		0	0	
...mean (sd)	46.47 (14.25)	44.40 (12.70)	0.15	40.89 (12.55)	41.43 (11.97)	-0.04	43.07 (13.24)	42.36 (12.20)	0.06
...median [IQR]	44.00 [37.00, 54.00]	43.00 [36.00, 51.00]	0.07	39.50 [34.00, 47.00]	40.00 [33.00, 47.00]	-0.04	41.26 (13.24)	40.93 (12.20)	0.03
...Missing; n (%)	27,576 (84.7%)	5,808 (84.5%)	0.01	50,290 (99.0%)	15,059 (99.2%)	-0.02	77,866 (93.4%)	20,867 (94.6%)	-0.05
Lab result number- LDL level (mg/dl) mean (only =<5000 included)	4,959	1,056		493	120		0	0	
...mean (sd)	105.33 (44.86)	108.39 (47.33)	-0.07	97.96 (50.99)	99.60 (50.63)	-0.03	100.84 (48.69)	102.34 (49.63)	-0.03
...median [IQR]	104.00 [77.00, 132.00]	109.75 [81.00, 135.75]	-0.12	96.50 [69.00, 129.00]	100.00 [71.00, 135.50]	-0.07	99.43 (48.69)	103.04 (49.63)	-0.07
...Missing; n (%)	27,597 (84.8%)	5,816 (84.6%)	0.01	50,302 (99.0%)	15,067 (99.2%)	-0.02	77,899 (93.5%)	20,883 (94.7%)	-0.05
Lab result number- Total cholesterol (mg/dl) mean (only =<5000 included)	5,021	1,066		508	129		0	0	
...mean (sd)	189.22 (50.40)	195.25 (47.32)	-0.12	188.61 (58.77)	191.70 (62.84)	-0.05	188.85 (55.65)	192.81 (58.45)	-0.07
...median [IQR]	184.00 [155.50, 217.00]	192.00 [163.38, 224.00]	-0.16	185.50 [152.00, 223.00]	187.00 [148.50, 223.00]	-0.02	184.91 (55.65)	188.56 (58.45)	-0.06
...Missing; n (%)	27,535 (84.6%)	5,806 (84.5%)	0.00	50,287 (99.0%)	15,058 (99.2%)	-0.02	77,822 (93.4%)	20,864 (94.6%)	-0.05
Lab result number- Triglyceride level (mg/dl) mean (only =<5000 included)	4,939	1,070		496	127		0	0	
...mean (sd)	169.72 (134.74)	186.28 (155.47)	-0.11	211.56 (177.58)	215.24 (191.85)	-0.02	195.22 (162.20)	206.22 (181.30)	-0.06
...median [IQR]	138.50 [99.00, 199.00]	150.00 [106.00, 215.25]	-0.08	168.00 [116.00, 243.12]	160.50 [110.00, 229.00]	0.04	156.48 (162.20)	157.23 (181.30)	0.00
...Missing; n (%)	27,617 (84.8%)	5,802 (84.4%)	0.01	50,299 (99.0%)	15,060 (99.2%)	-0.02	77,916 (93.5%)	20,862 (94.6%)	-0.05
Lab result number- Hemoglobin mean (only >0 included)	4,722	930		321	90		0	0	
...mean (sd)	13.97 (1.77)	14.57 (1.65)	-0.35	443.73 (7,701.64)	14.32 (1.38)	0.08	275.87 (6012.28)	14.40 (1.47)	0.06
...median [IQR]	14.10 [12.90, 15.20]	14.70 [13.60, 15.70]	-0.35	13.80 [12.92, 15.20]	14.43 [13.67, 15.15]	0.00	13.92 (6012.28)	14.51 (1.47)	0.00
...Missing; n (%)	27,834 (85.5%)	5,942 (86.5%)	-0.03	50,474 (99.4%)	15,097 (99.4%)	0.00	78,308 (93.9%)	21,039 (95.4%)	-0.07
Lab result number- Serum sodium mean (only > 90 and < 190 included)	6,132	1,249		425	138		0	0	
...mean (sd)	139.85 (2.82)	139.76 (2.52)	0.03	138.74 (2.71)	138.76 (2.93)	-0.01	139.17 (2.75)	139.07 (2.81)	0.04
...median [IQR]	140.00 [138.00, 142.00]	140.00 [138.00, 141.00]	0.00	139.00 [137.00, 140.50]	139.00 [137.00, 141.00]	0.00	139.39 (2.75)	139.31 (2.81)	0.03
...Missing; n (%)	26,424 (81.2%)	5,623 (81.8%)	-0.02	50,370 (99.2%)	15,049 (99.1%)	0.01	76,794 (92.1%)	20,672 (93.7%)	-0.06
Lab result number- Albumin mean (only >0 and <=10 included)	5,624	1,178		360	115		0	0	
...mean (sd)	4.20 (0.34)	4.29 (0.32)	-0.27	4.07 (0.63)	4.13 (0.53)	-0.10	4.12 (0.54)	4.18 (0.47)	-0.12
...median [IQR]	4.20 [4.00, 4.40]	4.30 [4.10, 4.50]	-0.30	4.15 [4.00, 4.40]	4.20 [4.00, 4.40]	-0.09	4.17 (0.54)	4.23 (0.47)	-0.12
...Missing; n (%)	26,932 (82.7%)	5,694 (82.9%)	-0.01	50,435 (99.3%)	15,072 (99.2%)	0.01	77,367 (92.8%)	20,766 (94.1%)	-0.05
Lab result number- Glucose (fasting or random) mean (only 10-1000 included)	6,067	1,242		408	132		0	0	
...mean (sd)	124.84 (56.69)	120.87 (51.78)	0.07	168.32 (67.53)	165.62 (78.32)	0.04	151.34 (63.52)	151.68 (71.12)	-0.01
...median [IQR]	105.00 [93.00, 135.00]	103.00 [92.50, 130.00]	0.04	149.00 [119.00, 202.50]	143.90 [111.00, 189.50]	0.07	131.81 (63.52)	131.16 (71.12)	0.01

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)	26,489 (81.4%)	5,630 (81.9%)	-0.01	50,387 (99.2%)	15,055 (99.1%)	0.01	76,876 (92.2%)	20,685 (93.8%)	-0.06
Lab result number- Potassium mean (only 1-7 included)	6,316	1,277		437	141		0	0	
...mean (sd)	4.39 (0.45)	4.40 (0.42)	-0.02	4.30 (0.46)	4.32 (0.47)	-0.04	4.34 (0.46)	4.34 (0.46)	0.00
...median [IQR]	4.40 [4.10, 4.66]	4.40 [4.10, 4.70]	0.00	4.30 [4.00, 4.60]	4.30 [4.00, 4.65]	0.00	4.34 (0.46)	4.33 (0.46)	0.02
...Missing; n (%)	26,240 (80.6%)	5,595 (81.4%)	-0.02	50,358 (99.1%)	15,046 (99.1%)	0.00	76,598 (91.9%)	20,641 (93.6%)	-0.07
Comorbidity Scores									
CCI (180 days)- ICD9 and ICD10									
...mean (sd)	2.89 (2.14)	2.20 (1.82)	0.35	1.95 (1.72)	1.61 (1.42)	0.22	2.32 (1.90)	1.79 (1.56)	0.30
...median [IQR]	2.00 [1.00, 4.00]	2.00 [1.00, 3.00]	0.00	1.00 [1.00, 3.00]	1.00 [1.00, 2.00]	0.00	1.39 (1.90)	1.31 (1.56)	0.05
Frailty Score (mean): Empirical Version 365 days,									
...mean (sd)	0.19 (0.05)	0.17 (0.04)	0.44	0.17 (0.04)	0.16 (0.03)	0.28	0.18 (0.04)	0.16 (0.03)	0.57
...median [IQR]	0.18 [0.16, 0.21]	0.17 [0.15, 0.19]	0.22	0.17 [0.15, 0.19]	0.16 [0.14, 0.18]	0.28	0.17 (0.04)	0.16 (0.03)	0.28
Healthcare Utilization									
Any hospitalization; n (%)	32,547 (100.0%)	6,871 (100.0%)	#DIV/0!	50,794 (100.0%)	15,186 (100.0%)	#DIV/0!	83,341 (100.0%)	22,057 (100.0%)	#DIV/0!
Any hospitalization during prior 31-180 days; n (%)	1,329 (4.1%)	212 (3.1%)	0.05	1,545 (3.0%)	367 (2.4%)	0.04	2,874 (3.4%)	0,579 (2.6%)	0.05
Endocrinologist Visit; n (%)	1,341 (4.1%)	327 (4.8%)	-0.03	1,666 (3.3%)	558 (3.7%)	-0.02	3,007 (3.6%)	0,885 (4.0%)	-0.02
Endocrinologist Visit (30 days prior); n (%)	689 (2.1%)	175 (2.5%)	-0.03	891 (1.8%)	317 (2.1%)	-0.02	1,580 (1.9%)	0,492 (2.2%)	-0.02
Endocrinologist Visit (31 to 180 days prior); n (%)	852 (2.6%)	194 (2.8%)	-0.01	1,002 (2.0%)	339 (2.2%)	-0.01	1,854 (2.2%)	0,533 (2.4%)	-0.01
Internal medicine/family medicine visits; n (%)	25,743 (79.1%)	4,863 (70.8%)	0.19	32,636 (64.3%)	9,499 (62.5%)	0.04	58,379 (70.0%)	14,362 (65.1%)	0.10
Internal medicine/family medicine visits (30 days prior) ; n (%)	21,362 (65.6%)	3,940 (57.3%)	0.17	20,203 (39.8%)	5,719 (37.7%)	0.04	41,565 (49.9%)	9,659 (43.8%)	0.12
Internal medicine/family medicine visits (31 to 180 days prior) ; n (%)	17,880 (54.9%)	3,050 (44.4%)	0.21	26,087 (51.4%)	7,448 (49.0%)	0.05	43,967 (52.7%)	10,498 (47.6%)	0.10
Cardiologist visit; n (%)	31,306 (96.2%)	6,623 (96.4%)	-0.01	17,435 (34.3%)	5,005 (33.0%)	0.03	48,741 (58.5%)	11,628 (52.7%)	0.12
Number of Cardiologist visits (30 days prior); n (%)	31,169 (95.7%)	6,604 (96.1%)	-0.02	14,457 (28.5%)	4,266 (28.1%)	0.01	45,626 (54.7%)	10,870 (49.3%)	0.11
Number of Cardiologist visits (31 to 180 days prior); n (%)	5,961 (18.3%)	919 (13.4%)	0.13	5,678 (11.2%)	1,313 (8.6%)	0.09	11,639 (14.0%)	2,232 (10.1%)	0.12
Electrocardiogram ; n (%)	30,299 (93.1%)	6,341 (92.3%)	0.03	29,074 (57.2%)	8,281 (54.5%)	0.05	59,373 (71.2%)	14,622 (66.3%)	0.11
Use of glucose test strips; n (%)	420 (1.3%)	70 (1.0%)	0.03	477 (0.9%)	157 (1.0%)	-0.01	0,897 (1.1%)	0,227 (1.0%)	0.01
Dialysis; n (%)	164 (0.5%)	27 (0.4%)	0.01	188 (0.4%)	20 (0.1%)	0.06	352 (0.4%)	47 (0.2%)	0.04
number of different/distinct medication prescriptions									
...mean (sd)	9.12 (4.59)	8.43 (4.41)	0.15	8.69 (4.31)	8.22 (4.10)	0.11	8.86 (4.42)	8.29 (4.20)	0.13
...median [IQR]	8.00 [6.00, 12.00]	7.00 [5.00, 11.00]	0.22	8.00 [5.00, 11.00]	7.00 [5.00, 10.00]	0.24	8.00 (4.42)	7.00 (4.20)	0.23
Number of Hospitalizations									
...mean (sd)	1.12 (0.38)	1.09 (0.31)	0.09	1.10 (0.33)	1.07 (0.28)	0.10	1.11 (0.35)	1.08 (0.29)	0.09
...median [IQR]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.00	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.00	1.00 (0.35)	1.00 (0.29)	0.00
Number of hospital days									
...mean (sd)	4.12 (3.05)	3.71 (2.07)	0.16	3.87 (2.26)	3.60 (1.70)	0.14	3.97 (2.60)	3.63 (1.82)	0.15
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 (2.60)	3.00 (1.82)	0.00

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Number of Emergency Department (ED) visits									
...mean (sd)	1.07 (1.31)	0.88 (1.12)	0.16	3.06 (5.31)	3.09 (5.66)	-0.01	2.28 (4.23)	2.40 (4.74)	-0.03
...median [IQR]	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	2.00 [0.00, 4.00]	2.00 [0.00, 4.00]	0.00	1.61 (4.23)	1.69 (4.74)	-0.02
Number of Office visits									
...mean (sd)	3.42 (3.55)	2.95 (3.26)	0.14	3.00 (3.50)	2.64 (3.14)	0.11	3.16 (3.52)	2.74 (3.18)	0.13
...median [IQR]	2.00 [1.00, 5.00]	2.00 [1.00, 4.00]	0.00	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.00	2.00 (3.52)	2.00 (3.18)	0.00
Number of Endocrinologist visits									
...mean (sd)	0.17 (1.23)	0.19 (1.29)	-0.02	0.14 (1.13)	0.18 (1.30)	-0.03	0.50 (1.20)	0.40 (1.25)	0.08
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.39 (1.20)	0.31 (1.25)	0.07
Number of internal medicine/family medicine visits									
...mean (sd)	7.06 (10.34)	5.39 (9.08)	0.17	3.96 (6.97)	3.52 (6.05)	0.07	5.17 (8.45)	4.10 (7.13)	0.14
...median [IQR]	4.00 [1.00, 9.00]	3.00 [0.00, 7.00]	0.10	2.00 [0.00, 5.00]	2.00 [0.00, 5.00]	0.00	2.78 (8.45)	2.31 (7.13)	0.06
Number of Cardiologist visits									
...mean (sd)	9.87 (6.11)	9.28 (5.43)	0.10	1.18 (2.77)	1.04 (2.36)	0.05	4.57 (4.39)	3.61 (3.61)	0.24
...median [IQR]	9.00 [6.00, 13.00]	8.00 [6.00, 12.00]	0.17	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	3.52 (4.39)	2.49 (3.61)	0.26
Number electrocardiograms received									
...mean (sd)	3.53 (2.68)	3.19 (2.39)	0.13	1.15 (1.49)	1.05 (1.41)	0.07	2.08 (2.04)	1.72 (1.77)	0.19
...median [IQR]	3.00 [2.00, 5.00]	3.00 [1.00, 4.00]	0.00	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0.00	1.78 (2.04)	1.62 (1.77)	0.08
Number of HbA1c tests ordered									
...mean (sd)	0.34 (0.67)	0.31 (0.64)	0.05	0.21 (0.53)	0.23 (0.55)	-0.04	0.26 (0.59)	0.25 (0.58)	0.02
...median [IQR]	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.59)	0.00 (0.58)	0.00
Number of glucose tests ordered									
...mean (sd)	0.17 (0.86)	0.15 (1.08)	0.02	0.12 (0.71)	0.12 (0.59)	0.00	0.14 (0.77)	0.13 (0.78)	0.01
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.77)	0.00 (0.78)	0.00
Number of lipid tests ordered									
...mean (sd)	0.50 (0.77)	0.49 (0.76)	0.01	0.37 (0.77)	0.43 (0.75)	-0.08	0.42 (0.77)	0.45 (0.75)	-0.04
...median [IQR]	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (0.77)	0.00 (0.75)	0.00
Number of creatinine tests ordered									
...mean (sd)	0.06 (0.32)	0.03 (0.24)	0.11	0.06 (0.37)	0.04 (0.34)	0.06	0.06 (0.35)	0.04 (0.31)	0.06
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.35)	0.00 (0.31)	0.00
Number of BUN tests ordered									
...mean (sd)	0.03 (0.30)	0.02 (0.38)	0.03	0.04 (0.36)	0.03 (0.25)	0.03	0.04 (0.34)	0.03 (0.30)	0.03
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.34)	0.00 (0.30)	0.00
Number of tests for microalbuminuria									
...mean (sd)	0.19 (0.64)	0.17 (0.63)	0.03	0.10 (0.46)	0.12 (0.49)	-0.04	0.14 (0.54)	0.14 (0.54)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.54)	0.00 (0.54)	0.00
Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level									
...mean (sd)	7.74 (9.49)	5.68 (8.22)	0.23	4.21 (7.22)	3.52 (6.47)	0.10	5.59 (8.18)	4.19 (7.06)	0.18
...median [IQR]	5.00 [0.00, 13.00]	0.00 [0.00, 9.00]	0.56	0.00 [0.00, 7.00]	0.00 [0.00, 4.00]	0.00	1.95 (8.18)	0.00 (7.06)	0.26
For PS									
Hemorrhagic stroke+Other cerebrovascular disease+Cerebrovascular procedure (for PS); n (%)	465 (1.4%)	44 (0.6%)	0.08	420 (0.8%)	47 (0.3%)	0.07	885 (1.1%)	91 (0.4%)	0.08

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of creatinine tests ordered (for PS); n (%)	1,365 (4.2%)	160 (2.3%)	0.11	2,291 (4.5%)	467 (3.1%)	0.07	3,656 (4.4%)	0,627 (2.8%)	0.09
Occurrence of BUN tests ordered (for PS); n (%)	761 (2.3%)	85 (1.2%)	0.08	1,388 (2.7%)	311 (2.0%)	0.05	2,149 (2.6%)	0,396 (1.8%)	0.05
Occurrence of chronic renal insufficiency w/o CKD (for PS) ; n (%)	2,591 (8.0%)	320 (4.7%)	0.14	1,642 (3.2%)	301 (2.0%)	0.08	4,233 (5.1%)	0,621 (2.8%)	0.12
Chronic kidney disease Stage 1-2 (for PS); n (%)	668 (2.1%)	86 (1.3%)	0.06	418 (0.8%)	101 (0.7%)	0.01	1086 (1.3%)	187 (0.8%)	0.05
Chronic kidney disease Stage 3-6 (for PS); n (%)	3,066 (9.4%)	323 (4.7%)	0.18	2,086 (4.1%)	312 (2.1%)	0.12	5,152 (6.2%)	0,635 (2.9%)	0.16
Bladder stones+Kidney stones (for PS); n (%)	744 (2.3%)	148 (2.2%)	0.01	879 (1.7%)	263 (1.7%)	0.00	1,623 (1.9%)	0,411 (1.9%)	0.00
Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) with ICD10 ; n (%)	1,023 (3.1%)	115 (1.7%)	0.09	646 (1.3%)	144 (0.9%)	0.04	1,669 (2.0%)	0,259 (1.2%)	0.06
Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%)	11 (0.0%)	2 (0.0%)	#DIV/0!	505 (1.0%)	170 (1.1%)	-0.01	516 (0.6%)	172 (0.8%)	-0.02
Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%)	138 (0.4%)	18 (0.3%)	0.02	511 (1.0%)	129 (0.8%)	0.02	0,649 (0.8%)	0,147 (0.7%)	0.01
Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) ; n (%)	14,046 (43.1%)	2,369 (34.5%)	0.18	15,374 (30.3%)	3,959 (26.1%)	0.09	29,420 (35.3%)	6,328 (28.7%)	0.14
Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) ; n (%)	32,053 (98.5%)	6,809 (99.1%)	-0.06	49,901 (98.2%)	14,978 (98.6%)	-0.03	81,954 (98.3%)	21,787 (98.8%)	-0.04
Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%)	4,843 (14.9%)	758 (11.0%)	0.12	4,841 (9.5%)	1,139 (7.5%)	0.07	9,684 (11.6%)	1,897 (8.6%)	0.10
Delirium + Psychosis (for PS); n (%)	215 (0.7%)	22 (0.3%)	0.06	162 (0.3%)	25 (0.2%)	0.02	377 (0.5%)	47 (0.2%)	0.05
Any use of Meglitinides (for PS); n (%)	63 (0.2%)	16 (0.2%)	0.00	146 (0.3%)	37 (0.2%)	0.02	209 (0.3%)	53 (0.2%)	0.02
Any use of AGIs (for PS); n (%)	21 (0.1%)	3 (0.0%)	0.04	36 (0.1%)	5 (0.0%)	0.04	29,420 (35.3%)	6,328 (28.7%)	0.14
CKD stage 3-6 + dialysis (for PS); n (%)	3,070 (9.4%)	324 (4.7%)	0.18	2,095 (4.1%)	314 (2.1%)	0.12	5,165 (6.2%)	0,638 (2.9%)	0.16
Use of thiazide; n (%)	2,836 (8.7%)	460 (6.7%)	0.08	3,685 (7.3%)	913 (6.0%)	0.05	73,405 (88.1%)	19,556 (88.7%)	-0.02
Use of beta blockers; n (%)	28,402 (87.2%)	5,986 (87.1%)	0.00	45,003 (88.6%)	13,570 (89.4%)	-0.03	17,365 (20.8%)	3,512 (15.9%)	0.13
Use of calcium channel blockers; n (%)	7,523 (23.1%)	1,165 (17.0%)	0.15	9,842 (19.4%)	2,347 (15.5%)	0.10	16,281 (19.5%)	4,174 (18.9%)	0.02
All antidiabetic medications except Insulin; n (%)	6,890 (21.2%)	1,389 (20.2%)	0.02	9,391 (18.5%)	2,785 (18.3%)	0.01	6,521 (7.8%)	1,373 (6.2%)	0.06
DM Medications - Insulin ; n (%)	2,879 (8.8%)	621 (9.0%)	-0.01	3,775 (7.4%)	1,127 (7.4%)	0.00	6,654 (8.0%)	1,748 (7.9%)	0.00
Use of Low Intensity Statins; n (%)	12,186 (37.4%)	2,249 (32.7%)	0.10	20,920 (41.2%)	5,246 (34.5%)	0.14	33106 (39.7%)	7,495 (34.0%)	0.12
Use of High Intensity Statins; n (%)	19,933 (61.2%)	4,628 (67.3%)	-0.13	28,101 (55.3%)	9,643 (63.5%)	-0.17	48034 (57.6%)	14,271 (64.7%)	-0.15
Malignant hypertension; n (%)	2,535 (7.8%)	300 (4.4%)	0.14	26,315 (51.8%)	7,468 (49.2%)	0.05	28850 (34.6%)	7,768 (35.2%)	-0.01
Cardiovascular stress test; n (%)	92 (0.3%)	7 (0.1%)	0.04	93 (0.2%)	21 (0.1%)	0.03	0,185 (0.2%)	28 (0.1%)	0.03
Echocardiogram; n (%)	22,726 (69.8%)	4,521 (65.8%)	0.09	31,917 (62.8%)	9,448 (62.2%)	0.01	54,643 (65.6%)	13969 (63.3%)	0.05
Number of BNP tests									
...mean (sd)	0.09 (0.38)	0.06 (0.29)	0.09	0.11 (0.37)	0.12 (0.37)	-0.03	0.10 (0.37)	0.10 (0.35)	0.00

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.37)	0.00 (0.35)	0.00
Number of Cardiac biomarkers tests (tropnin, CK-MBs, Myoglobin, CPK)									
...mean (sd)	0.54 (1.57)	0.41 (1.70)	0.08	0.73 (1.62)	0.80 (1.75)	-0.04	0.66 (1.60)	0.68 (1.73)	-0.01
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (1.60)	0.00 (1.73)	0.00
Number of Ambulatory Blood pressure monitoring tests									
...mean (sd)	0.00 (0.03)	0.00 (0.02)	0.00	0.00 (0.03)	0.00 (0.02)	0.00	0.00 (0.03)	0.00 (0.02)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.03)	0.00 (0.02)	0.00
N of days on antihypertensive medications during baseline									
...mean (sd)	85.76 (79.72)	67.64 (76.90)	0.23	75.26 (78.87)	62.73 (75.55)	0.16	79.36 (79.20)	64.26 (75.97)	0.19
...median [IQR]	88.00 [1.00, 174.00]	7.00 [1.00, 161.00]	1.03	31.00 [1.00, 168.00]	2.00 [1.00, 153.00]	0.38	53.26 (79.20)	3.56 (75.97)	0.64
N of days in database anytime prior									
...mean (sd)	1,683.97 (1,295.93)	1,631.68 (1,231.18)	0.04	1,749.68 (1,252.71)	1,712.87 (1,215.17)	0.03	1724.01 (1269.77)	1687.58 (1220.18)	0.03
...median [IQR]	1,324.00 [651.25, 2,398.00]	1,300.50 [633.00, 2,373.75]	0.02	1,412.00 [682.00, 2,626.00]	1,374.00 [702.00, 2,607.00]	0.03	1377.63 (1269.77)	1351.10 (1220.18)	0.02
Mean Copay for per prescription cost (charges in U.S. $) (180-1 day prior)									
...mean (sd)	23.49 (30.72)	25.23 (27.71)	-0.06	19.47 (32.84)	19.60 (23.87)	0.00	21.04 (32.03)	21.35 (25.13)	-0.01
...median [IQR]	15.00 [6.31, 30.00]	18.00 [8.00, 33.46]	-0.10	13.45 [5.38, 25.57]	13.28 [5.00, 26.50]	0.01	14.06 (32.03)	14.75 (25.13)	-0.02
...Missing; n (%)	4,763 (14.6%)	1,189 (17.3%)	-0.07	8,729 (17.2%)	2,756 (18.1%)	-0.02	13,492 (16.2%)	3945 (17.9%)	-0.05
Colonos; n (%)	1,036 (3.2%)	221 (3.2%)	0.00	1,556 (3.1%)	476 (3.1%)	0.00	2,592 (3.1%)	697 (3.2%)	-0.01
Fecal occult blood (FOB) test; n (%)	892 (2.7%)	216 (3.1%)	-0.02	1,516 (3.0%)	405 (2.7%)	0.02	2,408 (2.9%)	621 (2.8%)	0.01
Flu vaccine; n (%)	4,380 (13.5%)	793 (11.5%)	0.06	4,052 (8.0%)	1,152 (7.6%)	0.01	8,432 (10.1%)	1945 (8.8%)	0.04
Mammogram; n (%)	1,884 (5.8%)	312 (4.5%)	0.06	2,318 (4.6%)	545 (3.6%)	0.05	4,202 (5.0%)	857 (3.9%)	0.05
Pap smear; n (%)	580 (1.8%)	141 (2.1%)	-0.02	1,171 (2.3%)	348 (2.3%)	0.00	1,751 (2.1%)	489 (2.2%)	-0.01
Pneumonia vaccine; n (%)	3,945 (12.1%)	725 (10.6%)	0.05	2,330 (4.6%)	656 (4.3%)	0.01	6,275 (7.5%)	1381 (6.3%)	0.05
PSA test or Prostate exam for DRE; n (%)	4,334 (13.3%)	1,050 (15.3%)	-0.06	5,608 (11.0%)	2,061 (13.6%)	-0.08	9,942 (11.9%)	3111 (14.1%)	-0.07
Bone mineral density; n (%)	686 (2.1%)	105 (1.5%)	0.05	594 (1.2%)	103 (0.7%)	0.05	1,280 (1.5%)	208 (0.9%)	0.06
Use of Sympatomimetic agents; n (%)	261 (0.8%)	72 (1.0%)	-0.02	542 (1.1%)	186 (1.2%)	-0.01	0,803 (1.0%)	258 (1.2%)	-0.02
Use of CNS stimulants; n (%)	101 (0.3%)	29 (0.4%)	-0.02	267 (0.5%)	76 (0.5%)	0.00	0,368 (0.4%)	105 (0.5%)	-0.01
Use of estrogens, progestins, androgens; n (%)	946 (2.9%)	268 (3.9%)	-0.06	2,000 (3.9%)	656 (4.3%)	-0.02	2,946 (3.5%)	924 (4.2%)	-0.04
Use of Angiogenesis inhibitors; n (%)	14 (0.0%)	0 (0.0%)	#DIV/0!	29 (0.1%)	2 (0.0%)	0.04	0,043 (0.1%)	2 (0.0%)	0.04
Use of Oral Immunosuppressants; n (%)	63 (0.2%)	6 (0.1%)	0.03	128 (0.3%)	29 (0.2%)	0.02	0,191 (0.2%)	35 (0.2%)	0.00
Use of fondaparinux or Bivalirudin; n (%)	11 (0.0%)	3 (0.0%)	#DIV/0!	20 (0.0%)	2 (0.0%)	#DIV/0!	0,031 (0.0%)	5 (0.0%)	#DIV/0!
Use of other direct thrombin inhibitors (lepirudin, desirudin, argatroban); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0,000 (0.0%)	0 (0.0%)	#DIV/0!
Use of Prasugrel ON CED; n (%)	418 (1.3%)	82 (1.2%)	0.01	428 (0.8%)	123 (0.8%)	0.00	0,846 (1.0%)	205 (0.9%)	0.01
Use of Prasugrel 180 to 1 day prior; n (%)	417 (1.3%)	90 (1.3%)	0.00	423 (0.8%)	135 (0.9%)	-0.01	0,840 (1.0%)	225 (1.0%)	0.00
Duration of index hospitalization (i.e. anchor hospitalization LOS)									

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...mean (sd)	3.61 (2.82)	3.37 (1.49)	0.11	3.58 (1.67)	3.38 (1.34)	0.13	3.59 (2.19)	3.38 (1.39)	0.11
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 (2.19)	3.00 (1.39)	0.00
Number of D-dimer tests									
...mean (sd)	0.04 (0.21)	0.02 (0.17)	0.10	0.05 (0.24)	0.06 (0.26)	-0.04	0.05 (0.23)	0.05 (0.24)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.23)	0.00 (0.24)	0.00
Numbe of CRP, high-sensitivity CRP tests									
...mean (sd)	0.05 (0.30)	0.04 (0.24)	0.04	0.04 (0.28)	0.04 (0.28)	0.00	0.04 (0.29)	0.04 (0.27)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.29)	0.00 (0.27)	0.00
Number of PT or aPTTt tests									
...mean (sd)	0.46 (1.66)	0.21 (0.99)	0.18	0.47 (1.28)	0.43 (1.01)	0.03	0.47 (1.44)	0.36 (1.00)	0.09
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.00	0.00 (1.44)	0.00 (1.00)	0.00
Number of Bleeding time tests									
...mean (sd)	0.00 (0.02)	0.00 (0.01)	0.00	0.00 (0.02)	0.00 (0.01)	0.00	0.00 (0.02)	0.00 (0.01)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.02)	0.00 (0.01)	0.00
HAS-BLED Score (ICD-9 and ICD-10), 180 days									
...mean (sd)	3.74 (0.76)	3.42 (0.67)	0.45	3.38 (0.65)	3.16 (0.50)	0.38	3.52 (0.70)	3.24 (0.56)	0.44
...median [IQR]	4.00 [3.00, 4.00]	3.00 [3.00, 4.00]	1.40	3.00 [3.00, 4.00]	3.00 [3.00, 3.00]	0.00	3.39 (0.70)	3.00 (0.56)	0.62
Drug eluting stent; n (%)	14,767 (45.4%)	3,976 (57.9%)	-0.25	21,794 (42.9%)	7,216 (47.5%)	-0.09	36,561 (43.9%)	11192 (50.7%)	-0.14
Bare metal stent; n (%)	21,714 (66.7%)	4,304 (62.6%)	0.09	23,619 (46.5%)	7,240 (47.7%)	-0.02	45,333 (54.4%)	11544 (52.3%)	0.04
Use of CYP inhibitors; n (%)	5,868 (18.0%)	1,035 (15.1%)	0.08	8,155 (16.1%)	2,209 (14.5%)	0.04	14,023 (16.8%)	3244 (14.7%)	0.06
Use of CYP inducers; n (%)	237 (0.7%)	32 (0.5%)	0.03	363 (0.7%)	83 (0.5%)	0.03	0,600 (0.7%)	115 (0.5%)	0.03
Commercial vs Medicare Advantage- Business Type Code - CORRECT ONE - TRUVEN									
...Commercial; n (%)	14,856 (45.6%)	4,721 (68.7%)	-0.48	15,837 (31.2%)	2,186 (14.4%)	0.41	30,693 (36.8%)	6907 (31.3%)	0.12
...Medicare Advantage; n (%)	17,700 (54.4%)	2,151 (31.3%)	0.48	34,958 (68.8%)	13,001 (85.6%)	-0.41	52,658 (63.2%)	15152 (68.7%)	-0.12
Commercial vs Medicare Advantage- Business Type Code									
...COM = COMMERCIAL; n (%)	14,856 (45.6%)	4,721 (68.7%)	-0.48	-	-	#VALUE!	14,856 (45.6%)	4,721 (68.7%)	-0.48
...MCR = MEDICARE; n (%)	17,700 (54.4%)	2,151 (31.3%)	0.48	-	-	#VALUE!	17,700 (54.4%)	2,151 (31.3%)	0.48
...MCD = MEDICAID; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	-	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
...NONE = NO BUSINESS LINE CODE (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	-	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	-	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
Commercial vs Medicare Advantage- Data Type									
...1 - Fee For Service; n (%)	-	-	#VALUE!	30,527 (60.1%)	11,547 (76.0%)	-0.35	30,527 (60.1%)	11,547 (76.0%)	-0.35
...2 - Encounter; n (%)	-	-	#VALUE!	4,431 (8.7%)	1,454 (9.6%)	-0.03	4,431 (8.7%)	1,454 (9.6%)	-0.03
...3 - Medicare; n (%)	-	-	#VALUE!	13,608 (26.8%)	1,922 (12.7%)	0.36	13,608 (26.8%)	1,922 (12.7%)	0.36
...4 - Medicare Encounter; n (%)	-	-	#VALUE!	2,229 (4.4%)	264 (1.7%)	0.16	2,229 (4.4%)	264 (1.7%)	0.16
Metropolitan Statistical Area - Urban (any MSA) vs Rural (non-MSA)									
...Urban; n (%)	-	-	#VALUE!	38,125 (75.1%)	11,909 (78.4%)	-0.08	38,125 (75.1%)	11,909 (78.4%)	-0.08
...Rural; n (%)	-	-	#VALUE!	1,177 (2.3%)	269 (1.8%)	0.04	1,177 (2.3%)	269 (1.8%)	0.04
...Unknown/Missing; n (%)	-	-	#VALUE!	11,493 (22.6%)	3,009 (19.8%)	0.07	11,493 (22.6%)	3,009 (19.8%)	0.07

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

N of Generic name drugs				0	0		0	0	
...mean (sd)	13.63 (11.66)	11.15 (10.53)	0.22	11.00 (9.22)	9.50 (8.53)	0.17	12.03 (10.24)	10.01 (9.20)	0.21
...median [IQR]	10.00 [5.00, 18.00]	8.00 [4.00, 15.00]	0.18	8.00 [5.00, 15.00]	7.00 [4.00, 12.00]	0.11	8.78 (10.24)	7.31 (9.20)	0.15
N of Brand name drugs				0	0		0	0	
...mean (sd)	3.10 (4.35)	3.81 (4.42)	-0.16	3.61 (4.23)	3.98 (4.17)	-0.09	3.41 (4.28)	3.93 (4.25)	-0.12
...median [IQR]	2.00 [0.00, 4.00]	2.00 [1.00, 5.00]	0	2.00 [1.00, 5.00]	2.00 [2.00, 5.00]	0	2.00 (4.28)	2.00 (4.25)	0.00

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

PS-matched									
	Optum			Truven			POOLED		
Variable	**Clopidogrel 75mg**	**Prasugrel 10mg**	**St. Diff.**	**Clopidogrel 75mg**	**Prasugrel 10mg**	**St. Diff.**	**Clopidogrel 75mg**	**Ticagrelor 90mg**	**St. Diff.**
Number of patients	**6,835**	**6,835**		**15,097**	**15,097**		**21,932**	**21,932**	
Age									
...mean (sd)	58.80 (11.42)	59.02 (10.25)	-0.02	55.93 (10.14)	56.12 (8.94)	-0.02	56.82 (10.56)	57.02 (9.37)	-0.02
...median [IQR]	58.00 [51.00, 67.00]	59.00 [52.00, 67.00]	-0.09	56.00 [49.00, 62.00]	57.00 [50.00, 62.00]	-0.10	56.62 (10.56)	57.62 (9.37)	-0.10
Age categories									
...18 - 54; n (%)	2,525 (36.9%)	2,314 (33.9%)	0.06	6,689 (44.3%)	6,235 (41.3%)	0.06	9,214 (42.0%)	8,549 (39.0%)	0.06
...55 - 64; n (%)	2,191 (32.1%)	2,291 (33.5%)	-0.03	6,340 (42.0%)	6,718 (44.5%)	-0.05	8,531 (38.9%)	9,009 (41.1%)	-0.04
...65 - 74; n (%)	1,458 (21.3%)	1,861 (27.2%)	-0.14	1,285 (8.5%)	1,832 (12.1%)	-0.12	2,743 (12.5%)	3,693 (16.8%)	-0.12
...>= 75; n (%)	661 (9.7%)	369 (5.4%)	0.16	783 (5.2%)	312 (2.1%)	0.17	1,444 (6.6%)	0,681 (3.1%)	0.16
Gender- United									
...Males; n (%)	5,252 (76.8%)	5,251 (76.8%)	0.00	12,060 (79.9%)	12,032 (79.7%)	0.00	17,312 (78.9%)	17,283 (78.8%)	0.00
...Females; n (%)	1,583 (23.2%)	1,584 (23.2%)	0.00	3,037 (20.1%)	3,065 (20.3%)	0.00	4,620 (21.1%)	4,649 (21.2%)	0.00
Region									
...Northeast; n (%)	516 (7.5%)	519 (7.6%)	0.00	2,390 (15.8%)	2,403 (15.9%)	0.00	2,906 (13.3%)	2,922 (13.3%)	0.00
...South; n (%)	3,490 (51.1%)	3,498 (51.2%)	0.00	3,829 (25.4%)	3,783 (25.1%)	0.01	7,319 (33.4%)	7,281 (33.2%)	0.00
...Midwest; n (%)	1,676 (24.5%)	1,655 (24.2%)	0.01	6,469 (42.8%)	6,518 (43.2%)	-0.01	8,145 (37.1%)	8,173 (37.3%)	0.00
...West; n (%)	1,153 (16.9%)	1,163 (17.0%)	0.00	2,181 (14.4%)	2,174 (14.4%)	0.00	3,334 (15.2%)	3,337 (15.2%)	0.00
...Unknown+missing; n (%)	N/A	N/A	#VALUE!	228 (1.5%)	219 (1.5%)	0.00	228 (1.0%)	219 (1.0%)	0.00
CV Covariates									
Ischemic heart disease; n (%)	6,835 (100.0%)	6,835 (100.0%)	#DIV/0!	15,097 (100.0%)	15,097 (100.0%)	#DIV/0!	21,932 (100.0%)	21,932 (100.0%)	#DIV/0!
Acute MI; n (%)	6,541 (95.7%)	6,548 (95.8%)	0.00	14,764 (97.8%)	14,756 (97.7%)	0.01	21305 (97.1%)	21304 (97.1%)	0.00
ACS/unstable angina; n (%)	2,496 (36.5%)	2,482 (36.3%)	0.00	4,708 (31.2%)	4,681 (31.0%)	0.00	7204 (32.8%)	7163 (32.7%)	0.00
Old MI; n (%)	711 (10.4%)	737 (10.8%)	-0.01	991 (6.6%)	1,009 (6.7%)	0.00	1702 (7.8%)	1746 (8.0%)	-0.01
Stable angina; n (%)	1,083 (15.8%)	1,064 (15.6%)	0.01	1,637 (10.8%)	1,655 (11.0%)	-0.01	2,720 (12.4%)	2,719 (12.4%)	0.00
Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)	6,630 (97.0%)	6,627 (97.0%)	0.00	13,761 (91.2%)	13,777 (91.3%)	0.00	20,391 (93.0%)	20,404 (93.0%)	0.00
Other atherosclerosis with ICD10 ; n (%)	115 (1.7%)	96 (1.4%)	0.02	185 (1.2%)	156 (1.0%)	0.02	300 (1.4%)	252 (1.1%)	0.03
Previous cardiac procedure (CABG or PTCA or Stent) ; n (%)	6,755 (98.8%)	6,749 (98.7%)	0.01	14,848 (98.4%)	14,847 (98.3%)	0.01	21603 (98.5%)	21596 (98.5%)	0.00
History of CABG or PTCA; n (%)	1,761 (25.8%)	1,624 (23.8%)	0.05	2,106 (13.9%)	1,980 (13.1%)	0.02	3,867 (17.6%)	3,604 (16.4%)	0.03
Any stroke; n (%)	298 (4.4%)	287 (4.2%)	0.01	369 (2.4%)	390 (2.6%)	-0.01	0,667 (3.0%)	0,677 (3.1%)	-0.01
Ischemic stroke (w and w/o mention of cerebral infarction); n (%)	297 (4.3%)	287 (4.2%)	0.00	369 (2.4%)	390 (2.6%)	-0.01	0,666 (3.0%)	0,677 (3.1%)	-0.01
Hemorrhagic stroke; n (%)	1 (0.0%)	0 (0.0%)	#DIV/0!	1 (0.0%)	0 (0.0%)	#DIV/0!	2 (0.0%)	0 (0.0%)	#DIV/0!
TIA; n (%)	53 (0.8%)	46 (0.7%)	0.01	64 (0.4%)	63 (0.4%)	0.00	117 (0.5%)	109 (0.5%)	0.00
Other cerebrovascular disease; n (%)	48 (0.7%)	43 (0.6%)	0.01	39 (0.3%)	46 (0.3%)	0.00	87 (0.4%)	89 (0.4%)	0.00
Late effects of cerebrovascular disease; n (%)	29 (0.4%)	28 (0.4%)	0.00	20 (0.1%)	21 (0.1%)	0.00	49 (0.2%)	49 (0.2%)	0.00
Cerebrovascular procedure; n (%)	3 (0.0%)	1 (0.0%)	#DIV/0!	7 (0.0%)	1 (0.0%)	#DIV/0!	10 (0.0%)	2 (0.0%)	#DIV/0!
Heart failure (CHF); n (%)	917 (13.4%)	939 (13.7%)	-0.01	1,558 (10.3%)	1,623 (10.8%)	-0.02	2,475 (11.3%)	2,562 (11.7%)	-0.01
Peripheral Vascular Disease (PVD) or PVD Surgery ; n (%)	336 (4.9%)	359 (5.3%)	-0.02	410 (2.7%)	413 (2.7%)	0.00	0,746 (3.4%)	0,772 (3.5%)	-0.01

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Atrial fibrillation; n (%)	404 (5.9%)	412 (6.0%)	0.00	543 (3.6%)	573 (3.8%)	-0.01	0,947 (4.3%)	0,985 (4.5%)	-0.01
Other cardiac dysrhythmia; n (%)	1,605 (23.5%)	1,626 (23.8%)	-0.01	2,685 (17.8%)	2,644 (17.5%)	0.01	4,290 (19.6%)	4,270 (19.5%)	0.00
Cardiac conduction disorders; n (%)	628 (9.2%)	638 (9.3%)	0.00	1,033 (6.8%)	957 (6.3%)	0.02	1661 (7.6%)	1595 (7.3%)	0.01
Other CVD; n (%)	1,884 (27.6%)	1,884 (27.6%)	0.00	3,058 (20.3%)	3,144 (20.8%)	-0.01	4,942 (22.5%)	5,028 (22.9%)	-0.01
Diabetes-related complications									
Diabetic retinopathy; n (%)	125 (1.8%)	139 (2.0%)	-0.01	139 (0.9%)	152 (1.0%)	-0.01	0,264 (1.2%)	0,291 (1.3%)	-0.01
Diabetes with other ophthalmic manifestations; n (%)	0 (0.0%)	6 (0.1%)	-0.04	90 (0.6%)	108 (0.7%)	-0.01	0,090 (0.4%)	0,114 (0.5%)	-0.01
Retinal detachment, vitreous hemorrhage, vitrectomy; n (%)	4 (0.1%)	1 (0.0%)	0.04	3 (0.0%)	4 (0.0%)	#DIV/0!	7 (0.0%)	5 (0.0%)	#DIV/0!
Retinal laser coagulation therapy; n (%)	14 (0.2%)	11 (0.2%)	0.00	25 (0.2%)	28 (0.2%)	0.00	39 (0.2%)	39 (0.2%)	0.00
Occurrence of Diabetic Neuropathy ; n (%)	355 (5.2%)	329 (4.8%)	0.02	326 (2.2%)	351 (2.3%)	-0.01	0,681 (3.1%)	0,680 (3.1%)	0.00
Occurrence of diabetic nephropathy with ICD10 ; n (%)	231 (3.4%)	237 (3.5%)	-0.01	196 (1.3%)	199 (1.3%)	0.00	0,427 (1.9%)	0,436 (2.0%)	-0.01
Hypoglycemia ; n (%)	66 (1.0%)	70 (1.0%)	0.00	129 (0.9%)	137 (0.9%)	0.00	0,195 (0.9%)	0,207 (0.9%)	0.00
Hyperglycemia; n (%)	537 (7.9%)	517 (7.6%)	0.01	693 (4.6%)	692 (4.6%)	0.00	1,230 (5.6%)	1,209 (5.5%)	0.00
Disorders of fluid electrolyte and acid-base balance; n (%)	797 (11.7%)	802 (11.7%)	0.00	1,038 (6.9%)	1,067 (7.1%)	-0.01	1,835 (8.4%)	1,869 (8.5%)	0.00
Diabetic ketoacidosis; n (%)	32 (0.5%)	21 (0.3%)	0.03	46 (0.3%)	53 (0.4%)	-0.02	78 (0.4%)	74 (0.3%)	0.02
Hyperosmolar hyperglycemic nonketotic syndrome (HONK); n (%)	16 (0.2%)	18 (0.3%)	-0.02	13 (0.1%)	14 (0.1%)	0.00	29 (0.1%)	32 (0.1%)	0.00
Diabetes with peripheral circulatory disorders with ICD-10 ; n (%)	114 (1.7%)	101 (1.5%)	0.02	111 (0.7%)	124 (0.8%)	-0.01	0,225 (1.0%)	0,225 (1.0%)	0.00
Diabetic Foot; n (%)	59 (0.9%)	54 (0.8%)	0.01	103 (0.7%)	91 (0.6%)	0.01	162 (0.7%)	145 (0.7%)	0.00
Gangrene ; n (%)	6 (0.1%)	4 (0.1%)	0.00	5 (0.0%)	9 (0.1%)	-0.04	11 (0.1%)	13 (0.1%)	0.00
Lower extremity amputation; n (%)	16 (0.2%)	22 (0.3%)	-0.02	18 (0.1%)	23 (0.2%)	-0.03	34 (0.2%)	45 (0.2%)	0.00
Osteomyelitis; n (%)	17 (0.2%)	16 (0.2%)	0.00	36 (0.2%)	21 (0.1%)	0.03	53 (0.2%)	37 (0.2%)	0.00
Skin infections ; n (%)	200 (2.9%)	239 (3.5%)	-0.03	402 (2.7%)	436 (2.9%)	-0.01	0,602 (2.7%)	0,675 (3.1%)	-0.02
Erectile dysfunction; n (%)	217 (3.2%)	238 (3.5%)	-0.02	334 (2.2%)	326 (2.2%)	0.00	0,551 (2.5%)	0,564 (2.6%)	-0.01
Diabetes with unspecified complication; n (%)	138 (2.0%)	147 (2.2%)	-0.01	245 (1.6%)	244 (1.6%)	0.00	0,383 (1.7%)	0,391 (1.8%)	-0.01
Diabetes mellitus without mention of complications; n (%)	2,146 (31.4%)	2,128 (31.1%)	0.01	3,904 (25.9%)	3,932 (26.0%)	0.00	6,050 (27.6%)	6,060 (27.6%)	0.00
Hypertension: 1 inpatient or 2 outpatient claims within 365 days; n (%)	4,975 (72.8%)	4,998 (73.1%)	-0.01	9,576 (63.4%)	9,586 (63.5%)	0.00	14,551 (66.3%)	14,584 (66.5%)	0.00
Hyperlipidemia ; n (%)	5,523 (80.8%)	5,550 (81.2%)	-0.01	9,909 (65.6%)	9,936 (65.8%)	0.00	15,432 (70.4%)	15,486 (70.6%)	0.00
Edema; n (%)	188 (2.8%)	182 (2.7%)	0.01	255 (1.7%)	260 (1.7%)	0.00	0,443 (2.0%)	0,442 (2.0%)	0.00
Renal Dysfunction (non-diabetic) ; n (%)	910 (13.3%)	933 (13.7%)	-0.01	1,193 (7.9%)	1,157 (7.7%)	0.01	2,103 (9.6%)	2,090 (9.5%)	0.00
Occurrence of acute renal disease ; n (%)	381 (5.6%)	403 (5.9%)	-0.01	474 (3.1%)	485 (3.2%)	-0.01	855 (3.9%)	888 (4.0%)	-0.01
Occurrence of chronic renal insufficiency; n (%)	523 (7.7%)	547 (8.0%)	-0.01	557 (3.7%)	553 (3.7%)	0.00	1,080 (4.9%)	1,100 (5.0%)	0.00
Chronic kidney disease ; n (%)	500 (7.3%)	524 (7.7%)	-0.02	533 (3.5%)	533 (3.5%)	0.00	1,033 (4.7%)	1,057 (4.8%)	0.00
CKD Stage 3-4; n (%)	287 (4.2%)	295 (4.3%)	0.00	257 (1.7%)	281 (1.9%)	-0.02	0,544 (2.5%)	0,576 (2.6%)	-0.01

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of hypertensive nephropathy; n (%)	397 (5.8%)	411 (6.0%)	-0.01	391 (2.6%)	410 (2.7%)	-0.01	788 (3.6%)	821 (3.7%)	-0.01
Occurrence of miscellaneous renal insufficiency ; n (%)	348 (5.1%)	358 (5.2%)	0.00	422 (2.8%)	412 (2.7%)	0.01	0,770 (3.5%)	0,770 (3.5%)	0.00
Glaucoma or cataracts ; n (%)	631 (9.2%)	573 (8.4%)	0.03	919 (6.1%)	896 (5.9%)	0.01	1,550 (7.1%)	1,469 (6.7%)	0.02
Cellulitis or abscess of toe; n (%)	36 (0.5%)	33 (0.5%)	0.00	41 (0.3%)	48 (0.3%)	0.00	77 (0.4%)	81 (0.4%)	0.00
Foot ulcer; n (%)	58 (0.8%)	52 (0.8%)	0.00	103 (0.7%)	91 (0.6%)	0.01	161 (0.7%)	143 (0.7%)	0.00
Bladder stones; n (%)	9 (0.1%)	7 (0.1%)	0.00	8 (0.1%)	8 (0.1%)	0.00	17 (0.1%)	15 (0.1%)	0.00
Kidney stones; n (%)	137 (2.0%)	143 (2.1%)	-0.01	271 (1.8%)	255 (1.7%)	0.01	0,408 (1.9%)	0,398 (1.8%)	0.01
Urinary tract infections (UTIs); n (%)	314 (4.6%)	303 (4.4%)	0.01	400 (2.6%)	439 (2.9%)	-0.02	0,714 (3.3%)	0,742 (3.4%)	-0.01
Dipstick urinalysis; n (%)	1,338 (19.6%)	1,363 (19.9%)	-0.01	3,037 (20.1%)	3,034 (20.1%)	0.00	4,375 (19.9%)	4,397 (20.0%)	0.00
Non-dipstick urinalysis; n (%)	653 (9.6%)	659 (9.6%)	0.00	1,171 (7.8%)	1,211 (8.0%)	-0.01	1,824 (8.3%)	1,870 (8.5%)	-0.01
Urine function test; n (%)	114 (1.7%)	105 (1.5%)	0.02	186 (1.2%)	189 (1.3%)	-0.01	0,300 (1.4%)	0,294 (1.3%)	0.01
Cytology; n (%)	50 (0.7%)	45 (0.7%)	0.00	98 (0.6%)	85 (0.6%)	0.00	148 (0.7%)	130 (0.6%)	0.01
Cystos; n (%)	66 (1.0%)	60 (0.9%)	0.01	121 (0.8%)	112 (0.7%)	0.01	187 (0.9%)	172 (0.8%)	0.01
Other Covariates									
Liver disease; n (%)	4 (0.1%)	2 (0.0%)	0.04	6 (0.0%)	5 (0.0%)	#DIV/0!	0,010 (0.0%)	0,007 (0.0%)	#DIV/0!
Osteoarthritis; n (%)	790 (11.6%)	793 (11.6%)	0.00	1,138 (7.5%)	1,162 (7.7%)	-0.01	1,928 (8.8%)	1,955 (8.9%)	0.00
Other arthritis, arthropathies and musculoskeletal pain; n (%)	2,079 (30.4%)	2,059 (30.1%)	0.01	3,709 (24.6%)	3,698 (24.5%)	0.00	5,788 (26.4%)	5,757 (26.2%)	0.00
Dorsopathies; n (%)	1,460 (21.4%)	1,456 (21.3%)	0.00	2,421 (16.0%)	2,477 (16.4%)	-0.01	3,881 (17.7%)	3,933 (17.9%)	-0.01
Fractures; n (%)	110 (1.6%)	115 (1.7%)	-0.01	209 (1.4%)	208 (1.4%)	0.00	0,319 (1.5%)	0,323 (1.5%)	0.00
Falls ; n (%)	72 (1.1%)	85 (1.2%)	-0.01	53 (0.4%)	54 (0.4%)	0.00	125 (0.6%)	139 (0.6%)	0.00
Osteoporosis; n (%)	127 (1.9%)	137 (2.0%)	-0.01	141 (0.9%)	149 (1.0%)	-0.01	0,268 (1.2%)	0,286 (1.3%)	-0.01
Hyperthyroidism; n (%)	32 (0.5%)	34 (0.5%)	0.00	55 (0.4%)	37 (0.2%)	0.04	87 (0.4%)	71 (0.3%)	0.02
Hypothyroidism ; n (%)	653 (9.6%)	674 (9.9%)	-0.01	1,002 (6.6%)	986 (6.5%)	0.00	1,655 (7.5%)	1,660 (7.6%)	0.00
Other disorders of thyroid gland ; n (%)	136 (2.0%)	131 (1.9%)	0.01	208 (1.4%)	222 (1.5%)	-0.01	0,344 (1.6%)	0,353 (1.6%)	0.00
Depression; n (%)	635 (9.3%)	631 (9.2%)	0.00	899 (6.0%)	903 (6.0%)	0.00	1,534 (7.0%)	1,534 (7.0%)	0.00
Anxiety; n (%)	726 (10.6%)	716 (10.5%)	0.00	988 (6.5%)	993 (6.6%)	0.00	1,714 (7.8%)	1,709 (7.8%)	0.00
Sleep_Disorder; n (%)	566 (8.3%)	590 (8.6%)	-0.01	1,245 (8.2%)	1,207 (8.0%)	0.01	1,811 (8.3%)	1,797 (8.2%)	0.00
Dementia; n (%)	21 (0.3%)	22 (0.3%)	0.00	41 (0.3%)	38 (0.3%)	0.00	62 (0.3%)	60 (0.3%)	0.00
Delirium; n (%)	19 (0.3%)	20 (0.3%)	0.00	20 (0.1%)	23 (0.2%)	-0.03	39 (0.2%)	43 (0.2%)	0.00
Psychosis; n (%)	2 (0.0%)	2 (0.0%)	#DIV/0!	2 (0.0%)	2 (0.0%)	#DIV/0!	4 (0.0%)	4 (0.0%)	#DIV/0!
Obesity; n (%)	1,558 (22.8%)	1,593 (23.3%)	-0.01	2,340 (15.5%)	2,314 (15.3%)	0.01	3,898 (17.8%)	3,907 (17.8%)	0.00
Overweight; n (%)	239 (3.5%)	254 (3.7%)	-0.01	274 (1.8%)	257 (1.7%)	0.01	0,513 (2.3%)	0,511 (2.3%)	0.00
Smoking; n (%)	3,226 (47.2%)	3,191 (46.7%)	0.01	4,904 (32.5%)	4,789 (31.7%)	0.02	8,130 (37.1%)	7,980 (36.4%)	0.01
Alcohol abuse or dependence; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	176 (1.2%)	169 (1.1%)	0.01	176 (0.8%)	169 (0.8%)	0.00
Drug abuse or dependence; n (%)	1 (0.0%)	2 (0.0%)	#DIV/0!	1 (0.0%)	0 (0.0%)	#DIV/0!	2 (0.0%)	2 (0.0%)	#DIV/0!
COPD; n (%)	630 (9.2%)	673 (9.8%)	-0.02	953 (6.3%)	958 (6.3%)	0.00	1,583 (7.2%)	1,631 (7.4%)	-0.01
Asthma; n (%)	391 (5.7%)	397 (5.8%)	0.00	620 (4.1%)	616 (4.1%)	0.00	1,011 (4.6%)	1,013 (4.6%)	0.00
Obstructive sleep apnea; n (%)	645 (9.4%)	628 (9.2%)	0.01	1,057 (7.0%)	1,038 (6.9%)	0.00	1,702 (7.8%)	1,666 (7.6%)	0.01
Pneumonia; n (%)	210 (3.1%)	237 (3.5%)	-0.02	328 (2.2%)	357 (2.4%)	-0.01	0,538 (2.5%)	0,594 (2.7%)	-0.01
Imaging; n (%)	126 (1.8%)	132 (1.9%)	-0.01	137 (0.9%)	131 (0.9%)	0.00	263 (1.2%)	263 (1.2%)	0.00
Other Medications									
Use of ACE inhibitors; n (%)	3,718 (54.4%)	3,724 (54.5%)	0.00	9,117 (60.4%)	9,031 (59.8%)	0.01	12,835 (58.5%)	12,755 (58.2%)	0.01
Use of ARBs; n (%)	1,134 (16.6%)	1,169 (17.1%)	-0.01	2,308 (15.3%)	2,326 (15.4%)	0.00	3,442 (15.7%)	3,495 (15.9%)	-0.01
Use of Loop Diuretics - United; n (%)	434 (6.3%)	448 (6.6%)	-0.01	690 (4.6%)	715 (4.7%)	0.00	1,124 (5.1%)	1,163 (5.3%)	-0.01
Use of other diuretics- United; n (%)	215 (3.1%)	249 (3.6%)	-0.03	488 (3.2%)	516 (3.4%)	-0.01	0,703 (3.2%)	0,765 (3.5%)	-0.02

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Use of nitrates-United; n (%)	3,016 (44.1%)	2,968 (43.4%)	0.01	6,873 (45.5%)	6,878 (45.6%)	0.00	9,889 (45.1%)	9,846 (44.9%)	0.00
Use of other hypertension drugs; n (%)	239 (3.5%)	270 (4.0%)	-0.03	514 (3.4%)	512 (3.4%)	0.00	0,753 (3.4%)	0,782 (3.6%)	-0.01
Use of digoxin- United; n (%)	58 (0.8%)	49 (0.7%)	0.01	95 (0.6%)	94 (0.6%)	0.00	153 (0.7%)	143 (0.7%)	0.00
Use of Anti-arrhythmics; n (%)	84 (1.2%)	88 (1.3%)	-0.01	178 (1.2%)	170 (1.1%)	0.01	262 (1.2%)	258 (1.2%)	0.00
Use of COPD/asthma meds- United; n (%)	737 (10.8%)	744 (10.9%)	0.00	1,626 (10.8%)	1,640 (10.9%)	0.00	2,363 (10.8%)	2,384 (10.9%)	0.00
Use of statins; n (%)	6,235 (91.2%)	6,239 (91.3%)	0.00	13,750 (91.1%)	13,729 (90.9%)	0.01	19,985 (91.1%)	19,968 (91.0%)	0.00
Use of other lipid-lowering drugs; n (%)	578 (8.5%)	598 (8.7%)	-0.01	1,382 (9.2%)	1,425 (9.4%)	-0.01	1,960 (8.9%)	2,023 (9.2%)	-0.01
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Warfarin); n (%)	167 (2.4%)	171 (2.5%)	-0.01	405 (2.7%)	393 (2.6%)	0.01	0,572 (2.6%)	0,564 (2.6%)	0.00
Use of heparin and other low-molecular weight heparins; n (%)	31 (0.5%)	29 (0.4%)	0.01	2 (0.0%)	2 (0.0%)	#DIV/0!	33 (0.2%)	31 (0.1%)	0.03
Use of NSAIDs; n (%)	868 (12.7%)	891 (13.0%)	-0.01	1,920 (12.7%)	1,952 (12.9%)	-0.01	2,788 (12.7%)	2,843 (13.0%)	-0.01
Use of oral corticosteroids; n (%)	936 (13.7%)	946 (13.8%)	0.00	1,934 (12.8%)	2,015 (13.3%)	-0.01	2,870 (13.1%)	2,961 (13.5%)	-0.01
Use of bisphosphonate (United); n (%)	45 (0.7%)	58 (0.8%)	-0.01	72 (0.5%)	82 (0.5%)	0.00	117 (0.5%)	140 (0.6%)	-0.01
Use of opioids- United; n (%)	1,585 (23.2%)	1,555 (22.8%)	0.01	3,186 (21.1%)	3,248 (21.5%)	-0.01	4,771 (21.8%)	4,803 (21.9%)	0.00
Use of antidepressants; n (%)	1,047 (15.3%)	1,049 (15.3%)	0.00	2,039 (13.5%)	2,076 (13.8%)	-0.01	3,086 (14.1%)	3,125 (14.2%)	0.00
Use of antipsychotics; n (%)	45 (0.7%)	44 (0.6%)	0.01	104 (0.7%)	107 (0.7%)	0.00	0,149 (0.7%)	0,151 (0.7%)	0.00
Use of anticonvulsants; n (%)	503 (7.4%)	494 (7.2%)	0.01	775 (5.1%)	783 (5.2%)	0.00	1,278 (5.8%)	1,277 (5.8%)	0.00
Use of lithium- United; n (%)	9 (0.1%)	7 (0.1%)	0.00	16 (0.1%)	17 (0.1%)	0.00	25 (0.1%)	24 (0.1%)	0.00
Use of Benzos- United; n (%)	646 (9.5%)	660 (9.7%)	-0.01	1,460 (9.7%)	1,411 (9.3%)	0.01	2,106 (9.6%)	2,071 (9.4%)	0.01
Use of anxiolytics/hypnotics- United; n (%)	334 (4.9%)	351 (5.1%)	-0.01	798 (5.3%)	809 (5.4%)	0.00	1,132 (5.2%)	1,160 (5.3%)	0.00
Use of dementia meds- United; n (%)	14 (0.2%)	14 (0.2%)	0.00	15 (0.1%)	13 (0.1%)	0.00	29 (0.1%)	27 (0.1%)	0.00
Use of antiparkinsonian meds- United; n (%)	60 (0.9%)	63 (0.9%)	0.00	122 (0.8%)	118 (0.8%)	0.00	0,182 (0.8%)	0,181 (0.8%)	0.00
Entresto (sacubitril/valsartan); n (%)	1 (0.0%)	2 (0.0%)	#DIV/0!	1 (0.0%)	2 (0.0%)	#DIV/0!	2 (0.0%)	4 (0.0%)	#DIV/0!
Labs									
Lab values- HbA1c (%) ; n (%)	709 (10.4%)	663 (9.7%)	0.02	156 (1.0%)	129 (0.9%)	0.01	0,865 (3.9%)	0,792 (3.6%)	0.02
Lab values- HbA1c (%) (within 3 months) ; n (%)	447 (6.5%)	413 (6.0%)	0.02	105 (0.7%)	78 (0.5%)	0.03	0,552 (2.5%)	0,491 (2.2%)	0.02
Lab values- HbA1c (%) (within 6 months) ; n (%)	709 (10.4%)	663 (9.7%)	0.02	156 (1.0%)	129 (0.9%)	0.01	0,865 (3.9%)	0,792 (3.6%)	0.02
Lab values- BNP; n (%)	39 (0.6%)	31 (0.5%)	0.01	7 (0.0%)	6 (0.0%)	#DIV/0!	46 (0.2%)	37 (0.2%)	0.00
Lab values- BNP (within 3 months); n (%)	33 (0.5%)	26 (0.4%)	0.01	7 (0.0%)	5 (0.0%)	#DIV/0!	40 (0.2%)	31 (0.1%)	0.03
Lab values- BNP (within 6 months); n (%)	39 (0.6%)	31 (0.5%)	0.01	7 (0.0%)	6 (0.0%)	#DIV/0!	46 (0.2%)	37 (0.2%)	0.00
Lab values- BUN (mg/dl); n (%)	1,233 (18.0%)	1,236 (18.1%)	0.00	142 (0.9%)	143 (0.9%)	0.00	1,375 (6.3%)	1,379 (6.3%)	0.00
Lab values- BUN (mg/dl) (within 3 months); n (%)	769 (11.3%)	749 (11.0%)	0.01	98 (0.6%)	94 (0.6%)	0.00	0,867 (4.0%)	0,843 (3.8%)	0.01
Lab values- BUN (mg/dl) (within 6 months); n (%)	1,233 (18.0%)	1,236 (18.1%)	0.00	142 (0.9%)	143 (0.9%)	0.00	1,375 (6.3%)	1,379 (6.3%)	0.00
Lab values- Creatinine (mg/dl) ; n (%)	1,265 (18.5%)	1,267 (18.5%)	0.00	152 (1.0%)	152 (1.0%)	0.00	1,417 (6.5%)	1,419 (6.5%)	0.00
Lab values- Creatinine (mg/dl) (within 3 months) ; n (%)	789 (11.5%)	769 (11.3%)	0.01	103 (0.7%)	99 (0.7%)	0.00	0,892 (4.1%)	0,868 (4.0%)	0.01

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Lab values- Creatinine (mg/dl) (within 6 months) ; n (%)	1,265 (18.5%)	1,267 (18.5%)	0.00	152 (1.0%)	152 (1.0%)	0.00	1,417 (6.5%)	1,419 (6.5%)	0.00
Lab values- HDL level (mg/dl); n (%)	1,020 (14.9%)	1,056 (15.4%)	-0.01	154 (1.0%)	129 (0.9%)	0.01	1,174 (5.4%)	1,185 (5.4%)	0.00
Lab values- HDL level (mg/dl) (within 3 months); n (%)	596 (8.7%)	620 (9.1%)	-0.01	100 (0.7%)	84 (0.6%)	0.01	0,696 (3.2%)	0,704 (3.2%)	0.00
Lab values- HDL level (mg/dl) (within 6 months); n (%)	1,020 (14.9%)	1,056 (15.4%)	-0.01	154 (1.0%)	129 (0.9%)	0.01	1,174 (5.4%)	1,185 (5.4%)	0.00
Lab values- LDL level (mg/dl) ; n (%)	1,035 (15.1%)	1,065 (15.6%)	-0.01	163 (1.1%)	134 (0.9%)	0.02	1,198 (5.5%)	1,199 (5.5%)	0.00
Lab values- LDL level (mg/dl) (within 3 months) ; n (%)	601 (8.8%)	622 (9.1%)	-0.01	109 (0.7%)	86 (0.6%)	0.01	0,710 (3.2%)	0,708 (3.2%)	0.00
Lab values- LDL level (mg/dl) (within 6 months) ; n (%)	1,035 (15.1%)	1,065 (15.6%)	-0.01	163 (1.1%)	134 (0.9%)	0.02	1,198 (5.5%)	1,199 (5.5%)	0.00
Lab values- NT-proBNP; n (%)	6 (0.1%)	7 (0.1%)	0.00	1 (0.0%)	0 (0.0%)	#DIV/0!	7 (0.0%)	7 (0.0%)	#DIV/0!
Lab values- NT-proBNP (within 3 months); n (%)	3 (0.0%)	6 (0.1%)	-0.04	1 (0.0%)	0 (0.0%)	#DIV/0!	4 (0.0%)	6 (0.0%)	#DIV/0!
Lab values- NT-proBNP (within 6 months); n (%)	6 (0.1%)	7 (0.1%)	0.00	1 (0.0%)	0 (0.0%)	#DIV/0!	7 (0.0%)	7 (0.0%)	#DIV/0!
Lab values- Total cholesterol (mg/dl) ; n (%)	1,040 (15.2%)	1,059 (15.5%)	-0.01	158 (1.0%)	130 (0.9%)	0.01	1,198 (5.5%)	1,189 (5.4%)	0.00
Lab values- Total cholesterol (mg/dl) (within 3 months) ; n (%)	608 (8.9%)	617 (9.0%)	0.00	104 (0.7%)	84 (0.6%)	0.01	0,712 (3.2%)	0,701 (3.2%)	0.00
Lab values- Total cholesterol (mg/dl) (within 6 months) ; n (%)	1,040 (15.2%)	1,059 (15.5%)	-0.01	158 (1.0%)	130 (0.9%)	0.01	1,198 (5.5%)	1,189 (5.4%)	0.00
Lab values- Triglyceride level (mg/dl); n (%)	1,024 (15.0%)	1,061 (15.5%)	-0.01	149 (1.0%)	128 (0.8%)	0.02	1,173 (5.3%)	1,189 (5.4%)	0.00
Lab values- Triglyceride level (mg/dl) (within 3 months); n (%)	596 (8.7%)	619 (9.1%)	-0.01	96 (0.6%)	83 (0.5%)	0.01	0,692 (3.2%)	0,702 (3.2%)	0.00
Lab values- Triglyceride level (mg/dl) (within 6 months); n (%)	1,024 (15.0%)	1,061 (15.5%)	-0.01	149 (1.0%)	128 (0.8%)	0.02	1,173 (5.3%)	1,189 (5.4%)	0.00
Lab result number- HbA1c (%) mean (only 2 to 20 included)	705	659		134	117		0	0	
...mean (sd)	7.42 (1.91)	7.18 (1.76)	0.13	8.30 (1.99)	8.21 (1.99)	0.05	8.03 (1.97)	7.89 (1.92)	0.07
...median [IQR]	6.80 [6.00, 8.50]	6.60 [5.90, 8.00]	0.11	7.80 [6.70, 9.72]	7.60 [6.85, 9.45]	0.10	7.49 (1.97)	7.29 (1.92)	0.10
...Missing; n (%)	6,130 (89.7%)	6,176 (90.4%)	-0.02	14,963 (99.1%)	14,980 (99.2%)	-0.01	21,093 (96.2%)	21,156 (96.5%)	-0.02
Lab result number- BNP mean	39	31		7	6		0	0	
...mean (sd)	141.44 (237.21)	181.63 (295.19)	-0.15	149.07 (138.05)	98.17 (120.28)	0.39	146.69 (175.08)	124.18 (192.65)	0.12
...median [IQR]	41.00 [13.00, 131.00]	66.10 [31.00, 164.33]	-0.09	113.00 [42.50, 178.00]	55.00 [30.75, 161.50]	0.45	90.56 (175.08)	58.46 (192.65)	0.17
...Missing; n (%)	6,796 (99.4%)	6,804 (99.5%)	-0.01	15,090 (100.0%)	15,091 (100.0%)	#DIV/0!	21,886 (99.8%)	21,895 (99.8%)	0.00
Lab result number- BUN (mg/dl) mean	1,233	1,236		142	143		0	0	
...mean (sd)	16.90 (6.75)	17.50 (7.03)	-0.09	16.04 (4.95)	1,696.39 (14,189.00)	-0.17	16.31 (5.57)	1173.17 (11772.36)	-0.14
...median [IQR]	16.00 [13.00, 19.00]	16.00 [13.00, 20.00]	0.00	15.50 [13.00, 18.62]	16.50 [13.00, 21.00]	0.00	15.66 (5.57)	16.34 (11772.36)	0.00
...Missing; n (%)	5,602 (82.0%)	5,599 (81.9%)	0.00	14,955 (99.1%)	14,954 (99.1%)	0.00	20,557 (93.7%)	20,553 (93.7%)	0.00
Lab result number- Creatinine (mg/dl) mean (only 0.1 to 15 included)	1,250	1,258		145	136		1,395	1,394	
...mean (sd)	1.01 (0.33)	1.04 (0.43)	-0.08	0.97 (0.26)	1.06 (0.53)	-0.22	0.98 (0.28)	1.05 (0.50)	-0.17
...median [IQR]	0.96 [0.82, 1.12]	0.98 [0.83, 1.14]	-0.05	0.93 [0.83, 1.04]	1.00 [0.82, 1.19]	-0.17	0.94 (0.28)	0.99 (0.50)	-0.12

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)	5,585 (81.7%)	5,577 (81.6%)	0.00	14,952 (99.0%)	14,961 (99.1%)	-0.01	20,537 (93.6%)	20,538 (93.6%)	0.00
Lab result number- HDL level (mg/dl) mean (only =<5000 included)	1,020	1,056		154	127		1,174	1,183	
...mean (sd)	44.94 (13.33)	44.43 (12.73)	0.04	40.24 (12.24)	41.52 (11.98)	-0.11	41.70 (12.59)	42.43 (12.22)	-0.06
...median [IQR]	43.00 [36.00, 51.38]	43.00 [36.00, 51.00]	0.00	38.67 [32.00, 46.25]	40.00 [33.00, 47.00]	-0.11	40.02 (12.59)	40.93 (12.22)	-0.07
...Missing; n (%)	5,815 (85.1%)	5,779 (84.6%)	0.01	14,943 (99.0%)	14,970 (99.2%)	-0.02	20,758 (94.6%)	20,749 (94.6%)	0.00
Lab result number- LDL level (mg/dl) mean (only =<5000 included)	1,022	1,047		148	119		1,170	1,166	
...mean (sd)	109.40 (47.20)	108.64 (47.27)	0.02	101.12 (49.66)	99.27 (50.71)	0.04	103.70 (48.91)	102.19 (49.66)	0.03
...median [IQR]	107.00 [81.00, 138.00]	110.00 [81.00, 136.00]	-0.06	100.50 [74.00, 134.00]	100.00 [71.00, 134.00]	0.01	102.53 (48.91)	103.12 (49.66)	-0.01
...Missing; n (%)	5,813 (85.0%)	5,788 (84.7%)	0.01	14,949 (99.0%)	14,978 (99.2%)	-0.02	20,762 (94.7%)	20,766 (94.7%)	0.00
Lab result number- Total cholesterol (mg/dl) mean (only =<5000 included)	1,039	1,057		158	128		1,197	1,185	
...mean (sd)	195.21 (53.28)	195.39 (47.33)	0.00	192.59 (52.95)	191.62 (63.08)	0.02	193.41 (53.05)	192.79 (58.63)	0.01
...median [IQR]	190.00 [161.00, 222.00]	192.00 [163.75, 224.00]	-0.04	192.50 [154.00, 224.25]	187.00 [148.25, 223.00]	0.09	191.72 (53.05)	188.56 (58.63)	0.06
...Missing; n (%)	5,796 (84.8%)	5,778 (84.5%)	0.01	14,939 (99.0%)	14,969 (99.2%)	-0.02	20,735 (94.5%)	20,747 (94.6%)	0.00
Lab result number- Triglyceride level (mg/dl) mean (only =<5000 included)	1,023	1,061		149	126		1,172	1,187	
...mean (sd)	182.19 (149.91)	185.54 (154.25)	-0.02	219.48 (160.86)	215.70 (192.55)	0.02	207.86 (157.53)	206.30 (181.48)	0.01
...median [IQR]	147.00 [103.50, 216.00]	149.00 [106.00, 214.00]	-0.01	184.00 [127.50, 248.00]	162.25 [110.00, 232.00]	0.12	172.47 (157.53)	158.12 (181.48)	0.08
...Missing; n (%)	5,812 (85.0%)	5,774 (84.5%)	0.01	14,948 (99.0%)	14,971 (99.2%)	-0.02	20,760 (94.7%)	20,745 (94.6%)	0.00
Lab result number- Hemoglobin mean (only >0 included)	920	921		100	89		1,020	1,010	
...mean (sd)	14.50 (1.64)	14.57 (1.65)	-0.04	1,394.12	14.31 (1.39)	0.14	964.17 (11448.42)	14.39 (1.48)	0.12
...median [IQR]	14.70 [13.50, 15.60]	14.70 [13.60, 15.70]	0.00	14.35 [13.20, 15.40]	14.40 [13.65, 15.20]	0.00	14.46 (11448.42)	14.49 (1.48)	0.00
...Missing; n (%)	5,915 (86.5%)	5,914 (86.5%)	0.00	14,997 (99.3%)	15,008 (99.4%)	-0.01	20,912 (95.3%)	20,922 (95.4%)	0.00
Lab result number- Serum sodium mean (only > 90 and < 190 included)	1,213	1,237		143	137		1,356	1,374	
...mean (sd)	139.71 (2.67)	139.76 (2.52)	-0.02	138.34 (2.60)	138.76 (2.94)	-0.15	138.77 (2.62)	139.07 (2.82)	-0.11
...median [IQR]	140.00 [138.00, 141.00]	140.00 [138.00, 141.00]	0.00	138.40 [137.00, 140.00]	139.00 [137.00, 141.00]	-0.22	138.90 (2.62)	139.31 (2.82)	-0.15
...Missing; n (%)	5,622 (82.3%)	5,598 (81.9%)	0.01	14,954 (99.1%)	14,960 (99.1%)	0.00	20,576 (93.8%)	20,558 (93.7%)	0.00
Lab result number- Albumin mean (only >0 and <=10 included)	1,136	1,167		123	114		1,259	1,281	
...mean (sd)	4.29 (0.32)	4.28 (0.32)	0.03	4.18 (0.50)	4.13 (0.53)	0.10	4.21 (0.45)	4.18 (0.47)	0.07
...median [IQR]	4.30 [4.10, 4.50]	4.30 [4.10, 4.50]	0.00	4.20 [4.00, 4.40]	4.20 [4.00, 4.40]	0.00	4.23 (0.45)	4.23 (0.47)	0.00
...Missing; n (%)	5,699 (83.4%)	5,668 (82.9%)	0.01	14,974 (99.2%)	14,983 (99.2%)	0.00	20,673 (94.3%)	20,651 (94.2%)	0.00
Lab result number- Glucose (fasting or random) mean (only 10-1000 included)	1,198	1,230		132	131		1,330	1,361	
...mean (sd)	128.66 (60.29)	120.80 (51.79)	0.14	171.15 (68.93)	165.87 (78.57)	0.07	157.91 (66.36)	151.82 (71.31)	0.09
...median [IQR]	105.00 [92.50, 141.00]	103.00 [92.50, 129.25]	0.04	149.00 [118.25, 218.12]	144.00 [110.00, 190.00]	0.07	135.29 (66.36)	131.22 (71.31)	0.06

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)	5,637 (82.5%)	5,605 (82.0%)	0.01	14,965 (99.1%)	14,966 (99.1%)	0.00	20,602 (93.9%)	20,571 (93.8%)	0.00
Lab result number- Potassium mean (only 1-7 included)	1,240	1,265		141	140		1,381	1,405	
...mean (sd)	4.38 (0.42)	4.40 (0.42)	-0.05	4.30 (0.43)	4.31 (0.48)	-0.02	4.32 (0.43)	4.34 (0.46)	-0.04
...median [IQR]	4.40 [4.10, 4.60]	4.40 [4.10, 4.70]	0.00	4.30 [4.00, 4.59]	4.30 [4.00, 4.67]	0.00	4.33 (0.43)	4.33 (0.46)	0.00
...Missing; n (%)	5,595 (81.9%)	5,570 (81.5%)	0.01	14,956 (99.1%)	14,957 (99.1%)	0.00	20,551 (93.7%)	20,527 (93.6%)	0.00
Comorbidity Scores									
CCI (180 days)- ICD9 and ICD10									
...mean (sd)	2.17 (1.78)	2.20 (1.82)	-0.02	1.60 (1.45)	1.61 (1.43)	-0.01	1.78 (1.56)	1.79 (1.56)	-0.01
...median [IQR]	2.00 [1.00, 3.00]	2.00 [1.00, 3.00]	0.00	1.00 [1.00, 2.00]	1.00 [1.00, 2.00]	0.00	1.31 (1.56)	1.31 (1.56)	0.00
Frailty Score (mean): Empirical Version 365 days,									
...mean (sd)	0.17 (0.04)	0.17 (0.04)	0.00	0.16 (0.03)	0.16 (0.03)	0.00	0.16 (0.03)	0.16 (0.03)	0.00
...median [IQR]	0.17 [0.15, 0.19]	0.17 [0.15, 0.19]	0.00	0.16 [0.14, 0.18]	0.16 [0.14, 0.18]	0.00	0.16 (0.03)	0.16 (0.03)	0.00
Healthcare Utilization									
Any hospitalization; n (%)	6,832 (100.0%)	6,834 (100.0%)	#DIV/0!	15,097 (100.0%)	15,096 (100.0%)	#DIV/0!	21,929 (100.0%)	21,930 (100.0%)	#DIV/0!
Any hospitalization during prior 31-180 days; n (%)	178 (2.6%)	210 (3.1%)	-0.03	278 (1.8%)	351 (2.3%)	-0.04	0,456 (2.1%)	0,561 (2.6%)	-0.03
Endocrinologist Visit; n (%)	319 (4.7%)	323 (4.7%)	0.00	500 (3.3%)	556 (3.7%)	-0.02	0,819 (3.7%)	0,879 (4.0%)	-0.02
Endocrinologist Visit (30 days prior); n (%)	151 (2.2%)	173 (2.5%)	-0.02	275 (1.8%)	315 (2.1%)	-0.02	0,426 (1.9%)	0,488 (2.2%)	-0.02
Endocrinologist Visit (31 to 180 days prior); n (%)	221 (3.2%)	191 (2.8%)	0.02	287 (1.9%)	339 (2.2%)	-0.02	0,508 (2.3%)	0,530 (2.4%)	-0.01
Internal medicine/family medicine visits; n (%)	4,888 (71.5%)	4,835 (70.7%)	0.02	9,379 (62.1%)	9,434 (62.5%)	-0.01	14,267 (65.1%)	14,269 (65.1%)	0.00
Internal medicine/family medicine visits (30 days prior) ; n (%)	4,019 (58.8%)	3,918 (57.3%)	0.03	5,587 (37.0%)	5,685 (37.7%)	-0.01	9,606 (43.8%)	9,603 (43.8%)	0.00
Internal medicine/family medicine visits (31 to 180 days prior) ; n (%)	3,008 (44.0%)	3,037 (44.4%)	-0.01	7,347 (48.7%)	7,389 (48.9%)	0.00	10,355 (47.2%)	10,426 (47.5%)	-0.01
Cardiologist visit; n (%)	6,637 (97.1%)	6,586 (96.4%)	0.04	4,991 (33.1%)	4,966 (32.9%)	0.00	11,628 (53.0%)	11,552 (52.7%)	0.01
Number of Cardiologist visits (30 days prior); n (%)	6,615 (96.8%)	6,567 (96.1%)	0.04	4,217 (27.9%)	4,234 (28.0%)	0.00	10,832 (49.4%)	10,801 (49.2%)	0.00
Number of Cardiologist visits (31 to 180 days prior); n (%)	951 (13.9%)	910 (13.3%)	0.02	1,343 (8.9%)	1,297 (8.6%)	0.01	2,294 (10.5%)	2,207 (10.1%)	0.01
Electrocardiogram ; n (%)	6,232 (91.2%)	6,308 (92.3%)	-0.04	8,331 (55.2%)	8,225 (54.5%)	0.01	14,563 (66.4%)	14,533 (66.3%)	0.00
Use of glucose test strips; n (%)	73 (1.1%)	67 (1.0%)	0.01	140 (0.9%)	157 (1.0%)	-0.01	0,213 (1.0%)	0,224 (1.0%)	0.00
Dialysis; n (%)	22 (0.3%)	27 (0.4%)	-0.02	31 (0.2%)	20 (0.1%)	0.03	53 (0.2%)	47 (0.2%)	0.00
number of different/distinct medication prescriptions									
...mean (sd)	8.41 (4.29)	8.41 (4.40)	0.00	8.17 (4.00)	8.21 (4.09)	-0.01	8.24 (4.09)	8.27 (4.19)	-0.01
...median [IQR]	7.00 [5.00, 11.00]	7.00 [5.00, 11.00]	0.00	7.00 [5.00, 10.00]	7.00 [5.00, 10.00]	0.00	7.00 (4.09)	7.00 (4.19)	0.00
Number of Hospitalizations									
...mean (sd)	1.08 (0.30)	1.09 (0.31)	-0.03	1.07 (0.27)	1.07 (0.28)	0.00	1.07 (0.28)	1.08 (0.29)	-0.04
...median [IQR]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.00	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.00	1.00 (0.28)	1.00 (0.29)	0.00
Number of hospital days									
...mean (sd)	3.68 (2.09)	3.71 (2.08)	-0.01	3.60 (2.07)	3.60 (1.70)	0.00	3.62 (2.08)	3.63 (1.83)	-0.01
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 (2.08)	3.00 (1.83)	0.00

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Number of Emergency Department (ED) visits									
...mean (sd)	0.90 (1.06)	0.88 (1.13)	0.02	3.16 (5.52)	3.10 (5.67)	0.01	2.46 (4.62)	2.41 (4.75)	0.01
...median [IQR]	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	2.00 [0.00, 4.00]	2.00 [0.00, 4.00]	0.00	1.69 (4.62)	1.69 (4.75)	0.00
Number of Office visits									
...mean (sd)	2.95 (3.25)	2.94 (3.25)	0.00	2.59 (2.99)	2.64 (3.14)	-0.02	2.70 (3.07)	2.73 (3.17)	-0.01
...median [IQR]	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.00	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.00	2.00 (3.07)	2.00 (3.17)	0.00
Number of Endocrinologist visits									
...mean (sd)	0.21 (1.56)	0.19 (1.21)	0.01	0.14 (1.09)	0.18 (1.30)	-0.03	0.38 (1.08)	0.40 (1.25)	-0.02
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.31 (1.08)	0.31 (1.25)	0.00
Number of internal medicine/family medicine visits									
...mean (sd)	5.36 (9.27)	5.39 (9.09)	0.00	3.48 (6.29)	3.51 (6.05)	0.00	4.07 (7.35)	4.10 (7.14)	0.00
...median [IQR]	3.00 [0.00, 7.00]	3.00 [0.00, 7.00]	0.00	1.00 [0.00, 5.00]	2.00 [0.00, 5.00]	-0.16	1.62 (7.35)	2.31 (7.14)	-0.10
Number of Cardiologist visits									
...mean (sd)	9.25 (5.74)	9.28 (5.43)	-0.01	1.02 (2.32)	1.03 (2.35)	0.00	3.58 (3.74)	3.60 (3.60)	-0.01
...median [IQR]	8.00 [6.00, 12.00]	8.00 [6.00, 12.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	2.49 (3.74)	2.49 (3.60)	0.00
Number electrocardiograms received									
...mean (sd)	3.18 (2.35)	3.19 (2.39)	0.00	1.05 (1.36)	1.05 (1.41)	0.00	1.71 (1.73)	1.72 (1.77)	-0.01
...median [IQR]	3.00 [1.00, 4.00]	3.00 [1.00, 4.00]	0.00	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0.00	1.62 (1.73)	1.62 (1.77)	0.00
Number of HbA1c tests ordered									
...mean (sd)	0.30 (0.64)	0.31 (0.63)	-0.02	0.23 (0.55)	0.23 (0.55)	0.00	0.25 (0.58)	0.25 (0.58)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.58)	0.00 (0.58)	0.00
Number of glucose tests ordered									
...mean (sd)	0.13 (0.63)	0.15 (1.08)	-0.02	0.11 (0.51)	0.12 (0.59)	-0.02	0.12 (0.55)	0.13 (0.78)	-0.01
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.55)	0.00 (0.78)	0.00
Number of lipid tests ordered									
...mean (sd)	0.47 (0.75)	0.49 (0.76)	-0.03	0.42 (0.82)	0.42 (0.75)	0.00	0.44 (0.80)	0.44 (0.75)	0.00
...median [IQR]	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (0.80)	0.00 (0.75)	0.00
Number of creatinine tests ordered									
...mean (sd)	0.03 (0.25)	0.03 (0.24)	0.00	0.05 (0.32)	0.04 (0.34)	0.03	0.04 (0.30)	0.04 (0.31)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.30)	0.00 (0.31)	0.00
Number of BUN tests ordered									
...mean (sd)	0.02 (0.16)	0.02 (0.38)	0.00	0.03 (0.26)	0.03 (0.25)	0.00	0.03 (0.23)	0.03 (0.30)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.23)	0.00 (0.30)	0.00
Number of tests for microalbuminuria									
...mean (sd)	0.16 (0.57)	0.17 (0.62)	-0.02	0.11 (0.48)	0.12 (0.49)	-0.02	0.13 (0.51)	0.14 (0.53)	-0.02
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.51)	0.00 (0.53)	0.00
Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level									
...mean (sd)	5.70 (8.02)	5.68 (8.21)	0.00	3.49 (6.39)	3.53 (6.48)	-0.01	4.18 (6.94)	4.20 (7.06)	0.00
...median [IQR]	0.00 [0.00, 10.00]	0.00 [0.00, 9.00]	0.00	0.00 [0.00, 4.00]	0.00 [0.00, 4.00]	0.00	0.00 (6.94)	0.00 (7.06)	0.00
For PS									
Hemorrhagic stroke+Other cerebrovascular disease+Cerebrovascular procedure (for PS); n (%)	52 (0.8%)	44 (0.6%)	0.02	47 (0.3%)	47 (0.3%)	0.00	99 (0.5%)	91 (0.4%)	0.01

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of creatinine tests ordered (for PS); n (%)	178 (2.6%)	160 (2.3%)	0.02	479 (3.2%)	466 (3.1%)	0.01	0,657 (3.0%)	0,626 (2.9%)	0.01
Occurrence of BUN tests ordered (for PS); n (%)	92 (1.3%)	85 (1.2%)	0.01	290 (1.9%)	310 (2.1%)	-0.01	0,382 (1.7%)	0,395 (1.8%)	-0.01
Occurrence of chronic renal insufficiency w/o CKD (for PS) ; n (%)	298 (4.4%)	320 (4.7%)	-0.01	304 (2.0%)	298 (2.0%)	0.00	0,602 (2.7%)	0,618 (2.8%)	-0.01
Chronic kidney disease Stage 1-2 (for PS); n (%)	83 (1.2%)	85 (1.2%)	0.00	104 (0.7%)	100 (0.7%)	0.00	187 (0.9%)	185 (0.8%)	0.01
Chronic kidney disease Stage 3-6 (for PS); n (%)	306 (4.5%)	322 (4.7%)	-0.01	298 (2.0%)	309 (2.0%)	0.00	0,604 (2.8%)	0,631 (2.9%)	-0.01
Bladder stones+Kidney stones (for PS); n (%)	140 (2.0%)	148 (2.2%)	-0.01	274 (1.8%)	260 (1.7%)	0.01	0,414 (1.9%)	0,408 (1.9%)	0.00
Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) with ICD10 ; n (%)	124 (1.8%)	115 (1.7%)	0.01	146 (1.0%)	142 (0.9%)	0.01	0,270 (1.2%)	0,257 (1.2%)	0.00
Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%)	1 (0.0%)	2 (0.0%)	#DIV/0!	177 (1.2%)	169 (1.1%)	0.01	178 (0.8%)	171 (0.8%)	0.00
Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%)	17 (0.2%)	18 (0.3%)	-0.02	112 (0.7%)	128 (0.8%)	-0.01	0,129 (0.6%)	0,146 (0.7%)	-0.01
Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) ; n (%)	2,350 (34.4%)	2,362 (34.6%)	0.00	3,918 (26.0%)	3,941 (26.1%)	0.00	6,268 (28.6%)	6,303 (28.7%)	0.00
Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) ; n (%)	6,773 (99.1%)	6,772 (99.1%)	0.00	14,900 (98.7%)	14,889 (98.6%)	0.01	21,673 (98.8%)	21,661 (98.8%)	0.00
Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%)	739 (10.8%)	750 (11.0%)	-0.01	1,153 (7.6%)	1,132 (7.5%)	0.00	1,892 (8.6%)	1,882 (8.6%)	0.00
Delirium + Psychosis (for PS); n (%)	20 (0.3%)	22 (0.3%)	0.00	22 (0.1%)	25 (0.2%)	-0.03	42 (0.2%)	47 (0.2%)	0.00
Any use of Meglitinides (for PS); n (%)	11 (0.2%)	16 (0.2%)	0.00	36 (0.2%)	37 (0.2%)	0.00	47 (0.2%)	53 (0.2%)	0.00
Any use of AGIs (for PS); n (%)	2 (0.0%)	3 (0.0%)	#DIV/0!	3,918 (26.0%)	3,941 (26.1%)	0.00	6,268 (28.6%)	6,303 (28.7%)	0.00
CKD stage 3-6 + dialysis (for PS); n (%)	308 (4.5%)	323 (4.7%)	-0.01	299 (2.0%)	311 (2.1%)	-0.01	0,607 (2.8%)	0,634 (2.9%)	-0.01
Use of thiazide; n (%)	490 (7.2%)	459 (6.7%)	0.02	896 (5.9%)	910 (6.0%)	0.00	19,435 (88.6%)	19,440 (88.6%)	0.00
Use of beta blockers; n (%)	5,945 (87.0%)	5,953 (87.1%)	0.00	13,490 (89.4%)	13,487 (89.3%)	0.00	3,472 (15.8%)	3,490 (15.9%)	0.00
Use of calcium channel blockers; n (%)	1,164 (17.0%)	1,160 (17.0%)	0.00	2,308 (15.3%)	2,330 (15.4%)	0.00	4,161 (19.0%)	4,142 (18.9%)	0.00
All antidiabetic medications except Insulin; n (%)	1,371 (20.1%)	1,377 (20.1%)	0.00	2,790 (18.5%)	2,765 (18.3%)	0.01	1,386 (6.3%)	1,369 (6.2%)	0.00
DM Medications - Insulin ; n (%)	615 (9.0%)	614 (9.0%)	0.00	1,082 (7.2%)	1,116 (7.4%)	-0.01	1,697 (7.7%)	1,730 (7.9%)	-0.01
Use of Low Intensity Statins; n (%)	2,279 (33.3%)	2,243 (32.8%)	0.01	5,230 (34.6%)	5,227 (34.6%)	0.00	7509 (34.2%)	7,470 (34.1%)	0.00
Use of High Intensity Statins; n (%)	4,447 (65.1%)	4,598 (67.3%)	-0.05	9,372 (62.1%)	9,575 (63.4%)	-0.03	13819 (63.0%)	14,173 (64.6%)	-0.03
Malignant hypertension; n (%)	296 (4.3%)	300 (4.4%)	0.00	7,481 (49.6%)	7,421 (49.2%)	0.01	7777 (35.5%)	7,721 (35.2%)	0.01
Cardiovascular stress test; n (%)	7 (0.1%)	7 (0.1%)	0.00	16 (0.1%)	21 (0.1%)	0.00	0,023 (0.1%)	28 (0.1%)	0.00
Echocardiogram; n (%)	4,528 (66.2%)	4,503 (65.9%)	0.01	9,338 (61.9%)	9,391 (62.2%)	-0.01	13,866 (63.2%)	13894 (63.4%)	0.00
Number of BNP tests									
...mean (sd)	0.06 (0.32)	0.06 (0.29)	0.00	0.12 (0.37)	0.12 (0.37)	0.00	0.10 (0.36)	0.10 (0.35)	0.00

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.36)	0.00 (0.35)	0.00
Number of Cardiac biomarkers tests (tropnin, CK-MBs, Myoglobin, CPK)									
...mean (sd)	0.41 (1.47)	0.42 (1.70)	-0.01	0.79 (1.65)	0.80 (1.74)	-0.01	0.67 (1.60)	0.68 (1.73)	-0.01
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (1.60)	0.00 (1.73)	0.00
Number of Ambulatory Blood pressure monitoring tests									
...mean (sd)	0.00 (0.02)	0.00 (0.02)	0.00	0.00 (0.03)	0.00 (0.02)	0.00	0.00 (0.03)	0.00 (0.02)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.03)	0.00 (0.02)	0.00
N of days on antihypertensive medications during baseline									
...mean (sd)	67.42 (76.28)	67.51 (76.88)	0.00	62.89 (75.36)	62.70 (75.54)	0.00	64.30 (75.65)	64.20 (75.96)	0.00
...median [IQR]	7.00 [1.00, 158.00]	7.00 [1.00, 161.00]	0.00	1.00 [1.00, 152.00]	2.00 [1.00, 153.00]	-0.01	2.87 (75.65)	3.56 (75.96)	-0.01
N of days in database anytime prior									
...mean (sd)	1,616.01 (1,214.94)	1,629.92 (1,231.27)	-0.01	1,708.25 (1,223.37)	1,713.51 (1,215.39)	0.00	1679.50 (1220.75)	1687.46 (1220.36)	-0.01
...median [IQR]	1,302.00 [622.00, 2,331.00]	1,298.00 [631.00, 2,369.00]	0.00	1,365.00 [681.00, 2,602.50]	1,375.00 [702.00, 2,609.00]	-0.01	1345.37 (1220.75)	1351.00 (1220.36)	0.00
Mean Copay for per prescription cost (charges in U.S. $) (180-1 day prior)									
...mean (sd)	24.78 (29.15)	25.15 (27.70)	-0.01	19.46 (24.18)	19.56 (23.85)	0.00	21.12 (25.83)	21.30 (25.11)	-0.01
...median [IQR]	17.32 [6.94, 33.33]	17.92 [8.00, 33.33]	-0.02	13.33 [4.62, 26.99]	13.25 [5.00, 26.42]	0.00	14.57 (25.83)	14.71 (25.11)	-0.01
...Missing; n (%)	1,195 (17.5%)	1,189 (17.4%)	0.00	2,793 (18.5%)	2,751 (18.2%)	0.01	3,988 (18.2%)	3940 (18.0%)	0.01
Colonos; n (%)	233 (3.4%)	218 (3.2%)	0.01	476 (3.2%)	473 (3.1%)	0.01	0,709 (3.2%)	691 (3.2%)	0.00
Fecal occult blood (FOB) test; n (%)	215 (3.1%)	216 (3.2%)	-0.01	432 (2.9%)	404 (2.7%)	0.01	0,647 (3.0%)	620 (2.8%)	0.01
Flu vaccine; n (%)	784 (11.5%)	787 (11.5%)	0.00	1,142 (7.6%)	1,140 (7.6%)	0.00	1,926 (8.8%)	1927 (8.8%)	0.00
Mammogram; n (%)	323 (4.7%)	309 (4.5%)	0.01	546 (3.6%)	540 (3.6%)	0.00	0,869 (4.0%)	849 (3.9%)	0.01
Pap smear; n (%)	141 (2.1%)	138 (2.0%)	0.01	362 (2.4%)	347 (2.3%)	0.01	0,503 (2.3%)	485 (2.2%)	0.01
Pneumonia vaccine; n (%)	716 (10.5%)	723 (10.6%)	0.00	678 (4.5%)	649 (4.3%)	0.01	1,394 (6.4%)	1372 (6.3%)	0.00
PSA test or Prostate exam for DRE; n (%)	1,042 (15.2%)	1,040 (15.2%)	0.00	2,105 (13.9%)	2,048 (13.6%)	0.01	3,147 (14.3%)	3088 (14.1%)	0.01
Bone mineral density; n (%)	107 (1.6%)	105 (1.5%)	0.01	119 (0.8%)	103 (0.7%)	0.01	0,226 (1.0%)	208 (0.9%)	0.01
Use of Sympatomimetic agents; n (%)	73 (1.1%)	70 (1.0%)	0.01	170 (1.1%)	183 (1.2%)	-0.01	0,243 (1.1%)	253 (1.2%)	-0.01
Use of CNS stimulants; n (%)	32 (0.5%)	29 (0.4%)	0.01	83 (0.5%)	76 (0.5%)	0.00	0,115 (0.5%)	105 (0.5%)	0.00
Use of estrogens, progestins, androgens; n (%)	274 (4.0%)	261 (3.8%)	0.01	634 (4.2%)	643 (4.3%)	0.00	0,908 (4.1%)	904 (4.1%)	0.00
Use of Angiogenesis inhibitors; n (%)	2 (0.0%)	0 (0.0%)	#DIV/0!	15 (0.1%)	2 (0.0%)	0.04	0,017 (0.1%)	2 (0.0%)	0.04
Use of Oral Immunosuppressants; n (%)	4 (0.1%)	6 (0.1%)	0.00	38 (0.3%)	29 (0.2%)	0.02	0,042 (0.2%)	35 (0.2%)	0.00
Use of fondaparinux or Bivalirudin; n (%)	0 (0.0%)	3 (0.0%)	#DIV/0!	7 (0.0%)	2 (0.0%)	#DIV/0!	0,007 (0.0%)	5 (0.0%)	#DIV/0!
Use of other direct thrombin inhibitors (lepirudin, desirudin, argatroban); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0,000 (0.0%)	0 (0.0%)	#DIV/0!
Use of Prasugrel ON CED; n (%)	90 (1.3%)	82 (1.2%)	0.01	104 (0.7%)	122 (0.8%)	-0.01	0,194 (0.9%)	204 (0.9%)	0.00
Use of Prasugrel 180 to 1 day prior; n (%)	94 (1.4%)	90 (1.3%)	0.01	112 (0.7%)	134 (0.9%)	-0.02	0,206 (0.9%)	224 (1.0%)	-0.01
Duration of index hospitalization (i.e. anchor hospitalization LOS)									

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...mean (sd)	3.38 (1.65)	3.38 (1.50)	0.00	3.39 (1.39)	3.38 (1.34)	0.01	3.39 (1.48)	3.38 (1.39)	0.01
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 (1.48)	3.00 (1.39)	0.00
Number of D-dimer tests									
...mean (sd)	0.02 (0.17)	0.02 (0.17)	0.00	0.06 (0.26)	0.06 (0.26)	0.00	0.05 (0.24)	0.05 (0.24)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.24)	0.00 (0.24)	0.00
Numbe of CRP, high-sensitivity CRP tests									
...mean (sd)	0.04 (0.23)	0.04 (0.24)	0.00	0.04 (0.25)	0.04 (0.28)	0.00	0.04 (0.24)	0.04 (0.27)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.24)	0.00 (0.27)	0.00
Number of PT or aPTTt tests									
...mean (sd)	0.22 (1.04)	0.22 (0.99)	0.00	0.43 (0.98)	0.43 (1.00)	0.00	0.36 (1.00)	0.36 (1.00)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.00)	0.00 (1.00)	0.00
Number of Bleeding time tests									
...mean (sd)	0.00 (0.01)	0.00 (0.01)	0.00	0.00 (0.00)	0.00 (0.01)	0.00	0.00 (0.01)	0.00 (0.01)	0.00
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.01)	0.00 (0.01)	0.00
HAS-BLED Score (ICD-9 and ICD-10), 180 days									
...mean (sd)	3.41 (0.67)	3.42 (0.67)	-0.01	3.16 (0.49)	3.16 (0.50)	0.00	3.24 (0.55)	3.24 (0.56)	0.00
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 3.00]	3.00 [3.00, 3.00]	0.00	3.00 (0.55)	3.00 (0.56)	0.00
Drug eluting stent; n (%)	3,921 (57.4%)	3,947 (57.7%)	-0.01	7,223 (47.8%)	7,159 (47.4%)	0.01	11,144 (50.8%)	11106 (50.6%)	0.00
Bare metal stent; n (%)	4,286 (62.7%)	4,285 (62.7%)	0.00	7,177 (47.5%)	7,200 (47.7%)	0.00	11,463 (52.3%)	11485 (52.4%)	0.00
Use of CYP inhibitors; n (%)	1,028 (15.0%)	1,027 (15.0%)	0.00	2,162 (14.3%)	2,184 (14.5%)	-0.01	3,190 (14.5%)	3211 (14.6%)	0.00
Use of CYP inducers; n (%)	27 (0.4%)	32 (0.5%)	-0.01	94 (0.6%)	83 (0.5%)	0.01	0,121 (0.6%)	115 (0.5%)	0.01
Commercial vs Medicare Advantage-Business Type Code - CORRECT ONE - TRUVEN									
...Commercial; n (%)	4,740 (69.3%)	4,686 (68.6%)	0.02	2,090 (13.8%)	2,184 (14.5%)	-0.02	6,830 (31.1%)	6870 (31.3%)	0.00
...Medicare Advantage; n (%)	2,095 (30.7%)	2,149 (31.4%)	-0.02	13,007 (86.2%)	12,913 (85.5%)	0.02	15,102 (68.9%)	15062 (68.7%)	0.00
Commercial vs Medicare Advantage-Business Type Code									
...COM = COMMERCIAL; n (%)	4,740 (69.3%)	4,686 (68.6%)	0.02	-	-	#VALUE!	4,740 (69.3%)	4,686 (68.6%)	0.02
...MCR = MEDICARE; n (%)	2,095 (30.7%)	2,149 (31.4%)	-0.02	-	-	#VALUE!	2,095 (30.7%)	2,149 (31.4%)	-0.02
...MCD = MEDICAID; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	-	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
...NONE = NO BUSINESS LINE CODE (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	-	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	-	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
Commercial vs Medicare Advantage-Data Type									
...1 - Fee For Service; n (%)	-	-	#VALUE!	11,534 (76.4%)	11,465 (75.9%)	0.01	11,534 (76.4%)	11,465 (75.9%)	0.01
...2 - Encounter; n (%)	-	-	#VALUE!	1,473 (9.8%)	1,448 (9.6%)	0.01	1,473 (9.8%)	1,448 (9.6%)	0.01
...3 - Medicare; n (%)	-	-	#VALUE!	1,821 (12.1%)	1,920 (12.7%)	-0.02	1,821 (12.1%)	1,920 (12.7%)	-0.02
...4 - Medicare Encounter; n (%)	-	-	#VALUE!	269 (1.8%)	264 (1.7%)	0.01	269 (1.8%)	264 (1.7%)	0.01
Metropolitan Statistical Area - Urban (any MSA) vs Rural (non-MSA)									
...Urban; n (%)	-	-	#VALUE!	11,804 (78.2%)	11,827 (78.3%)	0.00	11,804 (78.2%)	11,827 (78.3%)	0.00
...Rural; n (%)	-	-	#VALUE!	260 (1.7%)	269 (1.8%)	-0.01	260 (1.7%)	269 (1.8%)	-0.01
...Unknown/Missing; n (%)	-	-	#VALUE!	3,033 (20.1%)	3,001 (19.9%)	0.01	3,033 (20.1%)	3,001 (19.9%)	0.01

Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

N of Generic name drugs									
...mean (sd)	11.18 (9.42)	11.14 (10.51)	0.00	9.48 (7.70)	9.50 (8.54)	-0.00246	10.01 (8.27)	10.01 (9.20)	0.00
...median [IQR]	8.00 [5.00, 15.00]	8.00 [4.00, 15.00]	0.00	7.00 [4.00, 12.00]	7.00 [4.00, 12.00]	0	7.31 (8.27)	7.31 (9.20)	0.00
N of Brand name drugs									
...mean (sd)	3.70 (5.32)	3.73 (4.20)	-0.01	3.86 (4.85)	3.93 (3.99)	-0.02	3.81 (5.00)	3.87 (4.06)	0.05
...median [IQR]	2.00 [1.00, 5.00]	2.00 [1.00, 5.00]	0.00	2.00 [1.00, 5.00]	2.00 [2.00, 5.00]	0	2.00 (5.00)	2.00 (4.06)	0.05